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  Abstract 
 
Investigating the Effect of Energy Substrates and LPS-activation on the In Vitro Energy 
Metabolism of BV-2, RAW264.7 and VM-M3 Cells  
 
Ashley Kaye Brown  
Advisor: Thomas N. Seyfried, Ph.D.  
 
 
Two major metabolic phenomena observed in cancer cells include the Warburg effect and 
Crabtree effect. The Crabtree effect is the in vitro inhibition of respiration by glucose. The 
influence of glucose on the oxygen consumption rate (OCR) and extracellular acidification rate 
(ECAR) of tumorigenic RAW264.7 and VM-M3 macrophage cells, as well as non-tumorigenic 
BV-2 microglia cells, was studied using the Seahorse XF96 extracellular flux analyzer. 
RAW264.7, VM-M3, and BV-2 cells incubated in glucose medium displayed a significantly 
lower OCR and higher ECAR compared to cells incubated in no glucose medium. Furthermore, 
when glucose medium was added to the RAW264.7 and BV-2 cells in real-time using the 
Seahorse XF96 injection ports, a rapid decrease in OCR and increase and ECAR was observed. 
Therefore, RAW264.7, VM-M3, and BV-2 cells display a robust Crabtree effect in vitro, as 
assessed by OCR and ECAR. Additionally, it is important to consider the Crabtree effect when 
studying in vitro energy metabolism of all cell and tissue types.  
 It was also found that the elimination of the Crabtree effect through glucose deprivation 
resulted in dynamic cardiolipin (CL) fatty acid changes in VM-M3 cells. VM-M3 cells incubated 
in 10 mM glucose medium for four hours displayed a short-chain, saturated (immature) CL fatty 
acid composition, while VM-M3 cells incubated in no glucose media for four hours displayed 
long-chain, unsaturated (mature) CL fatty acid composition. Cardiolipin (CL) is a phospholipid 
highly enriched in the inner mitochondrial membrane. Mature, long-chain, unsaturated CL 
molecular species are involved in maintaining mitochondrial function and membrane integrity. 
	  Overall, these data suggest that CL fatty acid composition may function as a structural 
component of the Crabtree effect in vitro.  
 The Warburg effect, or aerobic glycolysis, is the observation that tumor cells consume 
less oxygen and more glucose than normal, untransformed cells in the presence of oxygen. It has 
been shown that immune cells display a Warburg effect upon activation by changing their core 
metabolism from oxidative phosphorylation to glycolysis. In this study, it was observed that both 
RAW264.7 macrophage cells and BV-2 microglia cells display a significantly lower OCR and 
higher ECAR following LPS-activation. However, this observation is dependent on the 
concentration of LPS. Therefore, these data suggest that both RAW264.7 and BV-2 cells display 
a LPS concentration-dependent change in metabolism from oxidative phosphorylation to 
glycolysis upon LPS-activation in vitro.  
The in vitro lipid profiles that resulted from the Crabtree effect and the LPS-activated 
Warburg effect were also studied in the RAW264.7 cell line. The lipids phosphatidylserine (PS) 
and cardiolipin (CL) displayed the most robust changes in the RAW264.7 cells. Both PS and CL 
have been shown to be associated with cellular respiration.   
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A Note on Thesis Organization  
 
This thesis is organized into five individual chapters. Chapter one describes the Crabtree 
effect (inhibition of respiration by glucose) in BV-2 and RAW264.7 cells. Chapter two describes 
the Crabtree effect in VM-M3 cells and includes further research on the cardiolipin structural 
changes that occur in the VM-M3 cells after eliminating glucose from the culture media. Chapter 
three describes the metabolic changes that occur upon LPS-activation of the RAW264.7 and BV-
2 cells. Chapter four shows the lipid profile of RAW264.7 cells incubated in different energy 
substrates and activated with LPS. Finally, chapter five describes the implementation of an in 
vivo screening procedure to understand the variation in tumor growth and tumor burden that 
occurs within the VM-M3 mouse model.   
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CHAPTER 1 
 
ENERGY METABOLISM: THE CRABTREE EFFECT IN VITRO 
 
 
Background: Two main metabolic phenomena studied in cancer cells include the 
Warburg effect and Crabtree effect. Otto Warburg observed that in the presence of 
oxygen, tumor tissues consumed less oxygen and more glucose than normal tissues. This 
observation has been named the “Warburg effect.” While, Herbert Crabtree observed that 
the presence of glucose in culture media suppressed the respiration of tumor tissues, but 
not normal tissues. This observation has been named the “Crabtree effect.” 
 
Methodology and Principal Observations: This study focused on the Crabtree effect in 
vitro. The murine RAW264.7 and BV-2 macrophage cell lines were studied. The 
RAW264.7 cell line is a highly metastatic macrophage cell line, while the BV-2 cell line 
is a transformed, non-tumorigenic microglia (resident macrophage of the brain) cell line. 
Therefore, both cell lines are macrophage in origin; however, the RAW264.7 cells form 
tumors when implanted in vivo into BALB/c natural host mice, while the BV-2 cell line 
does not form tumors when implanted in vivo into C57BL/6 natural host mice.  
 
The Crabtree effect was measured in each cell line using the Seahorse XF96 Flux 
Analyzer. The oxygen consumption rate (OCR) and extracellular acidification rate 
(ECAR) of both RAW and BV-2 cells were obtained in media containing 10 mM glucose 
and media containing no glucose. The effect of adding glucose to both RAW and BV-2 
cells in real time was also studied in this assay. Media containing glucose was added to 
the cells incubated in no glucose media through the Seahorse XF96 injection ports.  
 
It was found that both the tumorigenic RAW264.7 cell line and non-tumorigenic BV-2 
cell line displayed a robust Crabtree effect in vitro. The addition of glucose in real-time to 
the culture media of RAW and BV-2 cells caused a significant and rapid decrease in 
oxygen consumption, as analyzed by the Seahorse XF96 extracellular flux analyzer.  
 
Conclusions and Significance: This study shows that both tumorigenic RAW and non-
tumorigenic BV-2 cell lines display the Crabtree effect in vitro. Therefore, the influence 
of glucose on metabolism must be considered when performing, analyzing, and 
understanding in vitro energy metabolism experiments.  
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Introduction: The Warburg and Crabtree Effect  
 
I. Overview: Cancer Metabolism: The Warburg Effect and the Crabtree Effect  
The Warburg Effect 
Cancer cells show great diversity in their type and etiology, yet often share 
metabolic abnormalities. Otto Warburg first described the metabolic abnormality of 
cancer cells more than half a century ago. Warburg observed that in the presence of 
oxygen tumor tissues consumed less oxygen and more glucose than normal, 
untransformed tissues (1–3). The reduced oxygen consumption of cancer cells that 
Warburg observed was concomitant with an increase in lactate fermentation. In 
Warburg’s 1956 paper “On the Origin of Cancer Cells” he stated, “With the ascites 
cancer cells of the mouse, for example, we find an average respiration of 7 cubic 
millimeters of oxygen consumed per milligram, per hour, and fermentation of 60 cubic 
millimeters of lactic acid produced per milligram, per hour. This, converted to energy 
equivalents, means that the cancer cells can obtain approximately the same amount of 
energy from fermentation as from respiration, whereas the normal body cells obtain much 
more energy from respiration than from fermentation” (2). This observation has been 
termed “aerobic glycolysis” or the “Warburg effect”, but it is unclear whether the 
increase in lactate in the presence of oxygen is due to respiratory insufficiency.  
In normal cells, the conversion of excess pyruvate into lactate is indicative of 
exposure to an environment that causes a respiratory insufficiency (hypoxia, respiratory 
poisons). Rather than producing energy through lactate fermentation, normal cell 
metabolism (e.g. neurons supplied with adequate oxygen) includes the conversion of 
glucose into pyruvate through glycolysis and the import of pyruvate into the 
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mitochondria (Appendix I). Upon entry into the mitochondria, pyruvate is oxidized to 
acetyl-CoA and enters the TCA cycle in order to produce the reducing equivalents 
necessary for oxidative phosphorylation. Therefore, Warburg concluded that the increase 
in lactate fermentation in cancer cells is indicative of insufficient mitochondrial 
respiration (1–3).  
In support of Warburg’s observations that respiration is insufficient in cancer cells 
compared to normal cells, both quantitative and qualitative mitochondrial insufficiencies 
have been observed in cancer cells. For example, Kiebish et al. found that mitochondria 
isolated from brain tumors in vivo had an abnormal cardiolipin (CL) profile that was 
associated with significant reductions in electron transport chain (ETC) activity (4). In 
addition, mitochondria content appears to be reduced in cancer cells (5).  However, the 
reason for the excess glucose consumed and lactate produced by cancer cells has not been 
established since some investigators are under the impression that genetic metabolic 
reprogramming drives the aerobic glycolysis (Warburg effect) (6).  
   
The Crabtree Effect  
 Another, less-studied, metabolic phenomena observed in vitro is the “Crabtree 
effect.” In his 1929 paper, “Observations on the Carbohydrate Metabolism of Tumors,” 
Herbert Crabtree observed that the oxygen consumption of both the Crocker sarcoma and 
Jensen’s rat sarcoma was lowered, on average, by 12% in the glucose-containing Ringer 
solution compared to the xylose-containing Ringer solution. Crabtree therefore concluded 
that glycolytic activity inhibited the tumor tissues’ capacity for respiration. (7). Since 
Crabtree’s seminal observation, many researchers have shown similar inhibitory effects 
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of carbohydrates on respiration in both cancer cells, such as Ehrlich ascites tumor cells 
and HeLa cells, and non-cancer tissues, such as pig platelets, coronary epithelium, guinea 
pig sperm, hamster embryos, and thymocytes, and, more recently, endothelial cells (8) 
(9).  
Initially, research focused on the inhibition of respiration by carbohydrates in 
Ehrlich ascites tumor cells. For example, Chance and Hess observed in 1961 that the 
respiration of ascites tumor cells was inhibited by the addition of glucose and proposed 
that this inhibition resulted from the observed increase in cytoplasmic ADP and decrease 
in cytoplasmic ATP, in conjunction with an accumulation of ATP and depletion of ADP 
in the mitochondria (10, 11). At the same time, Packer and Golder observed that light 
scattering in Ehrlich ascites tumor cells increases following the addition of glucose to the 
culture medium (12). Light scattering had previously been shown to increase after ADP 
addition and subsequent mitochondrial shrinkage in ascites tumor cells (13). Therefore, 
Packer and Golder suggested that the increase in light scattering supported the theories 
proposed by researchers such as Chance and Hess to explain the Crabtree effect. 
Shrunken mitochondria, which contain a high concentration of ATP and low 
concentration of ATP, increase light scattering (12). Packer and Golder were the first to 
describe structural changes that occur in conjunction with the Crabtree effect.  
The structural changes underlying the Crabtree effect were not comprehensively 
investigated until 2004 when Rossignol et al. were the first to study the structure and 
function of mitochondria in a transformed cell line (14). Rossignol et al. observed that 
HeLa cells grown in galactose medium displayed a two-fold higher respiratory rate 
compared to Hela cells grown in glucose medium (14). In addition, mitochondrial 
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morphology in HeLa cells grown in galactose medium was significantly different from 
HeLa cells grown in glucose medium (14). Cells grown in galactose medium contain 
more cristiae, an extended mitochondrial reticulum, and a condensed configuration 
compared to cells grown in glucose medium (14).  
In adding to this body of research on the Crabtree effect, the present study 
examines the Crabtree effect in RAW264.7 and BV-2 murine macrophage cell lines in 
real-time using the SeahorseXF96 Extracellular Flux Analyzer. RAW264.7 and BV-2 cell 
lines were chosen for this study due to the extensive use of these cells in research and 
subsequent studies on the LPS activation of these macrophage cells.  
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Materials and Methods  
 
 
Reagents 
Cell culture grade AlbuMAX I (Lipid Rich Bovine Serum Albumin) was obtained 
from gibco by Life Technologies (Grand island, NY, USA). AlbuMAX I (Albumax) 
contains the following fatty acids conjugated to BSA (the approximate concentration is 
indicated): Alpha-linolenic acid (0.59 mg FFA/g protein), Linoleic acid (0.65 mg FFA/g 
protein), Oleic acid (2.12 mg FFA/g protein), Stearic acid (2.09 mg FFA/g protein), and 
Palmitic acid (1.90 mg FFA/g protein).  
 
Cell lines and culture conditions 
The murine macrophage RAW264.7 cell line and the human microglia BV-2 cell 
line were purchased from American Type Culture Collection (Manassas, VA) BV-2 cells 
were derived from raf/myc-immortalized murine neonatal microglia. BV-2 cells do not 
form tumors when implanted in vivo into the natural C57BL/6 host. RAW264.7 cells 
were established from the ascites of a tumor induced in a male BAB/14 mouse by 
intraperitoneal injection of the Abelson Leukemia Virus (15). The BAB/14 mouse is a 
BALB/c congenic strain. The RAW264.7 cell line forms highly metastatic tumors when 
implanted in vivo into the natural BALB/c host.  
The cells were maintained in Dulbecco’s Modified Eagle’s Medium (DMEM, 
Sigma, St. Louis, MO) with high glucose (25mM) and supplemented with 10% fetal 
bovine serum (FBS, Sigma) and 50µg/ml penicillin-streptomycin (Sigma), and phenol 
red (Sigma) (DMEM complete media). The cells were maintained in a humidified 
incubator at 37ºC/5% CO2/95% air.  
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Measurement of oxygen consumption and extracellular acidification rates of RAW 
and BV-2 cells 
 
OCR and ECAR measurements were determined using the Seahorse XF96 
Extracellular Flux Analyzer. All steps in the preparation of the assay were performed at 
Boston College and the Seahorse assay was performed at Berg, LLC (Framingham, MA). 
In order to obtain each individual OCR and ECAR value, the Seahorse XF96 
Extracellular Flux Analyzer isolates 2 µL of media above the cell monolayer in each well 
of the micoplate to create a “transient microchamber.” Within this “transient 
microchamber” the Seahorse instrument measures the concentration of dissolved oxygen 
and free protons until the rate of change is linear. The slope of this rate of change graph is 
then used to calculate the flux of oxygen and free protons and record these values in units 
of pmol O2/min for OCR data and mpH/min for ECAR data. After obtaining 
measurements of dissolved oxygen and free protons in the “transient micochamber,” the 
sensors lift to allow the larger media volume to mix with the transient microchamber” to 
restore all values to baseline.  
RAW264.7, and BV-2 cells were plated in XF96 cell culture plates (Seahorse 
Bioscience, North Billerica, MA, USA) at near confluence. The cells were incubated for 
12 h in DMEM complete media. The medium was then changed to 75 uL of the 
appropriate Seahorse media containing no sodium bicarbonate or phenol red:  
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Glucose Seahorse Media No Glucose Seahorse Media 
DMEM DMEM 
10mM Glucose   
2 mM Glutamine 2 mM Glutamine  
0.5mg/mL Albumax I 0.5 mg/mL Albumax I 
5mM N-2-hydroxyethylpiperazine-N′-2-
ethanesulfonic acid (HEPES) buffer 
5mM N-2-hydroxyethylpiperazine-N′-2 
ethanesulfonic acid (HEPES) buffer 
50 µg/mL penicillin-streptomycin 50 µg/mL penicillin-streptomycin 
 
The plate was inserted into the Seahorse XF96 Extracellular Analyzer 2 hours after the 
medium was changed. The XF analyzer was programmed to take 2-minute measurements 
with a 1-min mix and 2-min equilibration period before each measurement.  
Real-time measurements of the effect of glucose on the oxygen consumption and 
extracellular acidification rates of RAW and BV-2 cells were also studied in this assay. 
25 µL of 40 mM glucose-Seahorse Media was injected through drug delivery port A of 
the Seahorse XF96 Flux Analyzer into wells containing no glucose media to obtain a 
final 10 mM glucose concentration. 25 µL of 10 mM glucose media was also injected 
through drug delivery port A into wells containing glucose media to ensure that changes 
in OCR or ECAR were not the result of different media volumes.  
 
Statistics  
Statistical analyses were performed on all data using IBM SPSS 21 Statistics 
Software. Two-tailed t-tests were performed and the significance values were determined 
where indicated. 	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Results  
 
OCR and ECAR: RAW264.7 cells  
The average OCR under the 10 mM glucose and under the no glucose conditions 
in the RAW264.7 cells was 516 ± 23 pmol/min and 645 ± 24 pmol/min, respectively (P < 
0.05) (Figure 1A).  The average ECAR under these same conditions was 55 ± 8 mpH/min 
and 13 ± 2 mpH/min, respectively (p <0.001)  (Figure 2A). These data showed that 
RAW264.7 cells under the no glucose condition displayed a significantly greater OCR 
and significantly lower ECAR compared to RAW cells under the glucose condition.  
The effect of glucose on the OCR and ECAR in the RAW264.7 cells was also 
assessed in real-time by injecting glucose seahorse media through drug delivery ports of 
the XF96 Flux Analyzer. After injecting glucose media, the OCR of RAW264.7 cells 
under the no glucose condition immediately decreased to a level below, and significantly 
different from, that of RAW264.7 cells under the 10mM glucose condition (Figure 1). 
The average OCR under the 10mM glucose and under the added glucose conditions was 
477 ± 28 pmol/min and 374 ± 9 pmol/min, respectively (p < 0.001) (Figure 1B). After 
injecting glucose media, the average ECAR of RAW264.7 cells under the no glucose 
condition immediately increased to a level above, but not significantly different from 
RAW cells in 10 mM glucose condition (Figure 2). The average ECAR under the 10 mM 
glucose and under the added glucose conditions was 55 ± 7 pmol/min and 60 ± 5 
mpH/min, respectively (Figure 2 Panel B).  
 After the initial decrease in OCR following glucose addition, the RAW cells to 
which glucose was added slowly increased their average OCR to a level that was not 
statistically significant from the 10 mM glucose media condition (Figure 1). The final 
	  10	  
OCR measurement in the assay shows no difference between the average OCR for RAW 
cells in 10mM glucose media and RAW cells to which glucose media was added (Figure 
1C).  
After the initial increase in the ECAR following glucose addition, the RAW cells 
to which glucose was added slowly decreased their ECAR. However, the final average 
ECAR measurement was not significantly different between the RAW cells under the 
glucose and added glucose conditions (Figure 2C).  
 
OCR and ECAR: BV-2 cells  
The average OCR under the 10 mM glucose and under the no glucose conditions 
in the BV-2 cells was 231 ± 8 pmol/min and 318 ± 3 pmol/min, respectively (P < 0.001).  
(Figure 3A).  The average ECAR under these same conditions was 23 ± 2 mpH/min and 
7 ± 2 mpH/min, respectively (p <0.001)  (Figure 4A). These data showed that BV-2 cells 
under the no glucose condition displayed a significantly greater OCR and significantly 
lower ECAR compared to RAW cells under the glucose condition. This is the same trend 
as the RAW246.7 cells.  
The effect of glucose on the OCR and ECAR in the BV-2 cells was also assessed 
in real-time by injecting glucose seahorse media through drug delivery ports of the XF96 
Flux Analyzer. After injecting glucose media, the OCR of BV-2 cells under the no 
glucose condition immediately decreased and the ECAR immediately increased to levels 
not significantly different from that of BV-2 cells under the 10 mM glucose condition 
(Figure 3 and 4). The average OCR under the 10mM glucose and under the added 
glucose conditions was 232 ± 9 pmol/min and 242 ± 2 pmol/min, respectively (Figure 
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3B). The average ECAR under the 10 mM glucose and under the added glucose 
conditions was 24 ± 2 mpH/min and 23 ± 2 mpH/min, respectively (Figure 4B).  
After the initial decrease in OCR following glucose addition, the BV-2 cells to 
which glucose was added further decreased their average OCR. However, this decrease 
was not statistically different from the 10 mM glucose media condition (Figure 3). The 
final OCR measurement in the assay shows no difference between the average OCR for 
BV-2 cells in 10mM glucose media and BV-2 cells to which glucose media was added 
(Figure 3C).  
After the initial increase in the ECAR following glucose addition, the ECAR 
measurements of the BV-2 cells to which glucose was added slowly decreased. However, 
the final average ECAR measurement was not significantly different between the BV-2 
cells under the glucose and added glucose conditions (Figure 4C).   
 Overall, both the tumorigenic RAW cells and non-tumorigenic BV-2 cells in the 
no glucose condition displayed a significantly higher oxygen consumption rate and a 
significantly lower extracellular acidification rate compared to the same cells incubated 
in 10 mM glucose condition. Furthermore, when glucose was added to the media of 
RAW and BV-2 cells, there was an immediate decrease in the oxygen consumption rate 
and an immediate increase in the extracellular acidification rate.  
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Discussion  
 
A real-time assessment of the Crabtree effect has not, to my knowledge, been 
previously performed using the Seahorse platform. In this study it was found that 
RAW264.7 and BV-2 cells display a robust and dynamic Crabtree effect in vitro. Upon 
addition of glucose to both the RAW246.7 and BV-2 cell lines, there was an immediate 
decrease in oxygen consumption and increase in extracellular acidification that occurred 
and was maintained for the duration of the assay. The decrease in oxygen consumption 
suggests a decrease in respiration following the addition of glucose. However, both non-
mitochondrial and mitochondrial oxygen consumption are measured in the Seahorse 
assay. Therefore, the amount of oxygen consumption directly associated with 
mitochondrial ATP production must be determined in order to assess the amount of 
oxygen consumption associated directly with respiration. Furthermore, the increase in 
ECAR is suggestive of an increase in glycolysis. However, this measurement must also 
be compared to a direct measurement of L-lactate, a product of glycolysis.  
Nevertheless, the above data show that both a highly metastatic macrophage cell 
line and a transformed, non-tumorigenic macrophage cell line display the Crabtree effect 
in vitro. Therefore, the Crabtree effect is not a phenomenon specific to tumorigenesis in 
vitro, which has been previously characterized in several studies (8, 13, 14, 16–18).  
Although both tumorigenic RAW and non-tumorigenic BV-2 cells display a 
Crabtree effect, the degree to which the OCR is suppressed and ECAR is increased by 
glucose is significantly different between these two cell lines. The tumorigenic 
RAW264.7 cell line had a significantly larger percent reduction in oxygen consumption 
compared to the BV-2 cells when glucose was added to the culture medium. The percent 
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decrease in OCR following the addition of glucose was 42 ± 2 % for RAW 264.7 cells 
and 23 ± 1 % for BV-2 cells (p < 0.001). These data suggest that the metabolism of the 
highly metastatic RAW264.7 cell line is more sensitive to the addition of glucose in the 
culture medium. The sensitivity of RAW264.7 cells to glucose is also displayed by the 
higher percent increase in ECAR following the addition of glucose. The percent increase 
in ECAR was 363 ± 54 % for RAW cells and 229 ± 80 % for BV-2 cells (p<0.001). 
Overall, RAW cells appear to have a greater sensitivity to glucose addition into their 
media, which may be a product of the tumorigenic and highly metastatic phenotype of 
these cells.  
From these data, it must also be noted that BV-2 cells exhibit an apparent high 
basal activation in vitro, which may influence the oxygen consumption and extracellular 
acidification of non-activated BV-2 cells (Chapter 3). A study by Leist et al. showed that 
LPS-activated BV-2 cells exhibited lower inflammatory gene transcription compared to 
LPS-activated primary microglia cells (19). The weaker response of BV-2 cells to LPS-
activation indicates that these cells may have a high basal activation. This high basal 
activation may subsequently influence the metabolism of BV-2 cells and may explain the 
weaker metabolic response of BV-2 cells to glucose. The basal activation of BV-2 cells 
also questions the validity of BV-2 cells as a non-tumorigenic control cell in metabolic 
studies.  
Another metabolic phenomenon that must also be considered alongside the 
Crabtree effect is the Warburg effect. Cells displaying a Warburg effect show greater 
lactate production in the presence of oxygen. Tumorigenic RAW cells displayed a high 
extracellular acidification rate in the glucose condition. This observation may result from 
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the Warburg effect. However, it is difficult to determine the individual contributions of 
the Warburg effect and the Crabtree effect to the high extracellular acidification of cells 
in the glucose condition. Furthermore, the relative contribution of glycolysis to the total 
extracellular acidification rate must be determined in order to further characterize the 
metabolic phenotype of RAW and BV-2 cells in the glucose and no glucose conditions. 
Previous studies performed by Roberto Flores showed a correlation between ECAR and 
lactate metabolite measurements (data not shown).  
The ability of transformed cells to improve their respiratory capacity when 
cultured in the absence of glucose has been previously characterized in HeLa cells (14). 
The rotenone-sensitive endogenous respiratory rate was significantly increased in HeLa 
cells grown in galactose medium compared to glucose medium (14). The increase in 
respiration when cells are grown in galactose medium compared to glucose medium may 
result from mitochondrial biogenesis or the increased synthesis of mitochondrial enzymes 
(14). In addition to an increase in respiration, HeLa cells grown in galactose media 
displayed increased respiratory protein levels as well as structural remodeling of 
mitochondria into a condensed conformation (14). Thus, structural changes underlie the 
improved oxidative phosphorylation capacity seen in HeLa cells grown in galactose 
media. An extension of the current study in RAW and BV-2 cells may characterize the 
possible structural changes of the mitochondria in these cells when grown in no glucose 
or galactose media. However, despite all of the data that may be collected in vitro 
showing a mitochondrial adaptation of transformed cells to energy substrate type, the in 
vivo adaptation of cells to energy substrate type may be different. The metabolism of 
cells grown in vivo in their natural host is regulated by a myriad of factors including 
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hormones, signaling molecules, and the overall metabolic state of the organism. 
Nevertheless, the majority of cell metabolism experiments are conducted in vitro due to 
various factors.  
The inhibition of respiration and increase in glycolysis in glucose media is an 
important consideration when conducting any metabolic analysis in vitro. Most in vitro 
experiments are conducted in high glucose (25 mM) DMEM media.  Therefore, such 
conditions may result in misleading in vitro metabolism data, as such high glucose 
conditions may not typically be found in vivo. For example, the growth of non-
tumorigenic cell types such as C2C12 murine myoblastic cell line in 25 mM glucose 
caused mitochondrial dysfunction, which is not seen in vivo (20). Therefore, the effect of 
the energy substrates on cells in vitro must be conducted before further metabolism 
experiments are performed. Additionally, the Crabtree effect may influence drug toxicity 
screens in vitro, as such conditions may not be indicative of in vivo cell behavior in the 
presence of the drug. This is particularly important when studying mitochondrial 
toxicants (21). The Crabtree effect may be modulating the effect of a mitochondrial 
toxicant in vitro such that when tested in vivo the mitochondrial toxicant is significantly 
more toxic to the organism.  
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Figure 1. Oxygen consumption rate (OCR) of RAW264.7 cells. RAW264.7 cells were 
incubated in Seahorse media containing glucose (10 mM) or no glucose for 2 hours 
before the start of the assay. Oxygen consumption rate (OCR) measurements were 
determined using an XF96 Extracellular Flux Analyzer. OCR measurements were 
obtained for each condition. The OCR for three indicated data points are expressed in bar 
graph format as the mean OCR ± SD (A-C). At 22 minutes, 25 µL of 40 mM glucose 
seahorse media was injected into the no glucose condition to produce a final glucose 
concentration of 10mM. 25ul of 10mM glucose media was also injected into the 10mM 
glucose condition to maintain the same media volume for all conditions in the assay. 
OCR measurements are expressed as the mean ± SD for each time point. Each point has n 
= 12 (no glucose) and n = 24 (10 mM glucose). ** indicates p < 0.001.  
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Figure 2. Extracellular acidification rate (ECAR) of RAW264.7 cells. RAW264.7 
cells were incubated in Seahorse media containing glucose (10 mM) or no glucose for 2 
hours before the start of the assay. Extracellular acidification rate (ECAR) measurements 
for each condition were determined using an XF96 Extracellular Flux Analyzer. The 
ECAR values for three indicated data points are expressed in bar graph format as the 
mean ECAR ± SD (A-C). At 22 minutes, 25 µL of 40 mM glucose seahorse media was 
injected into the no glucose condition to produce a final glucose concentration of 10 mM. 
25 µL of 10 mM glucose media was also injected into the 10 mM glucose condition to 
maintain the same media volume for all conditions in the assay. ECAR measurements are 
expressed as the mean ± SD for each time point. Each point has an n = 12 (no glucose) 
and n = 24 (10 mM glucose). ** indicates p < 0.001. 
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Figure 3. Oxygen consumption rate (OCR) of BV-2 cells. BV-2 cells were incubated 
in Seahorse media containing glucose (10 mM) or no glucose for 2 hours before the start 
of the assay. Oxygen consumption rate (OCR) measurements for each condition were 
determined using an XF96 Extracellular Flux Analyzer. The OCR for three indicated 
time points are expressed in bar graph format as the mean ± SD (A-C). At 29 minutes, 25 
µL of 40 mM glucose seahorse media was injected into the no glucose condition to 
produce a final glucose concentration of 10 mM. 25 µL of 10 mM glucose media was 
also injected into the 10 mM glucose condition to maintain the same media volume for all 
conditions in the assay. OCR measurements are expressed as the mean OCR ± SD for 
each time point. Each point has an n = 12 (no glucose) and n = 24 (10 mM glucose). ** 
indicates p < 0.001. 
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Figure 4. Extracellular acidification rate (ECAR) of BV-2 cells. BV-2 cells were 
incubated in Seahorse media containing glucose (10 mM) or no glucose for 2 hours 
before the start of the assay. Extracellular acidification rate (ECAR) measurements for 
each condition were determined using an XF96 Extracellular Flux Analyzer. The ECAR 
for three indicated time points are expressed in bar graph format as the mean ECAR ± SD 
(A-C). At 29 minutes, 25 µL of 40 mM glucose media was injected into the no glucose 
condition to produce a final glucose concentration of 10 mM. 25 µL of 10 mM glucose 
media was also injected into the 10 mM glucose condition to maintain the same media 
volume for all conditions in the assay. ECAR measurements are expressed as the mean 
ECAR ± SD for each time point. Each point has an n = 12 (no glucose) and n = 24 (10 
mM glucose). ** indicates p < 0.001. 
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CHAPTER 2 
 
ENERGY METABOLISM: THE CRABTREE EFFECT AND CARDIOLIPIN 
STRUCTURE IN VITRO 
 
 
Link to Chapter 1: Chapter one described the Crabtree effect in the RAW246.7 and BV-
2 murine macrophage cell lines. This chapter describes the Crabtree effect in another 
murine macrophage cell line: VM-M3. In addition to the Crabtree effect, this chapter also 
describes cardiolipin (CL) structural differences between VM-M3 cells grown in glucose 
and no glucose media.  
 
 
Background: Herbert Crabtree observed that the presence of glucose in culture media 
suppressed the respiration of tumor tissues, but not normal tissues. This observation has 
been named the “Crabtree effect.” The Crabtree effect, or the suppression of respiration 
by glucose, may be studied through oxygen consumption and extracellular acidification 
measurements, as shown previously. However, the respiration of a cell may also be 
studied by analyzing structural components involved in respiration. An example of such a 
structural component is the content and fatty acid chain composition of CL. CL is a 
phospholipid in the inner mitochondrial membrane and is involved in maintaining 
mitochondrial function and membrane integrity.  
 
CL content and composition in vivo and in vitro was previously studied by Kiebish et al. 
(4). This study provided a structural basis for the Warburg effect. However, analysis of 
both the tumorigenic VM-M3 cell line and non-tumorigenic astrocytes displayed an 
immature CL profile in vitro. It was expected that the non-tumorigenic cell line would 
display a mature CL profile in vitro similar to non-tumorigenic brain tissue in vivo. The 
immature CL profile of the non-tumorigenic astrocytes in vitro may be influenced by the 
Crabtree effect. In addition, the immature CL profile of the tumorigenic VM-M3 cell line 
may also be influenced by the Crabtree effect. Therefore, this study examined the 
possible influence of the Crabtree effect on the CL fatty acid profile of the tumorigenic 
VM-M3 cells line in vitro.  
 
 
Methodology and Principle Observations: This study focused on the Crabtree effect 
and the cardiolipin structural changes that occur in association with the Crabtree effect in 
the VM-M3 cell line.  The VM-M3 cell line is a highly metastatic macrophage cell line 
derived from a spontaneous brain tumor in the VM/Dk strain mouse in Dr. Seyfried’s 
laboratory. When the VM-M3 cell line is implanted in vivo into VM/Dk natural host 
mice, the VM-M3 cell line forms a primary tumor and metastasizes to all major organs.  
 
The Crabtree effect was measured in each cell line using the Seahorse XF96 Flux 
Analyzer. The Oxygen consumption rate (OCR) and extracellular acidification rate 
(ECAR) of both RAW and BV-2 cells were obtained in media containing 10 mM glucose 
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and media containing no glucose. It was found that the VM-M3 cell line displayed a 
robust Crabtree effect in vitro.  
 
CL content was analyzed by HPTLC and showed no significant difference between 
glucose (10mM) and no glucose conditions.  
 
CL fatty acid composition was analyzed by both gas chromatography and mass 
spectrometry. The sensitivity of mass spectrometry showed significant changes in 
cardiolipin structure occurred after incubating the VM-M3 cells in glucose (10mM) and 
no glucose media for 4 h.  
 
Conclusions and Significance: VM-M3 cells display the Crabtree effect, or suppression 
of oxygen consumption by glucose, in vitro. This was assessed through measuring the 
OCR and ECAR of the VM-M3 cells in glucose (10mM) and no glucose conditions. In 
association with the Crabtree effect is a change in CL fatty acid composition. VM-M3 
cells incubated in the glucose condition displayed a CL profile with more short-chain 
unsaturated (immature) CL molecular species. In contrast, VM-M3 cells incubated in the 
no glucose condition displayed a CL profile containing more long-chain unsaturated 
(mature) molecular species. Overall, these data display a correlation between oxygen 
consumption rate/ extracellular acidification rate and CL fatty acid composition. The 
higher oxygen consumption rate of VM-M3 cells incubated in no glucose medium is 
correlated with a mature CL molecular species profile.  
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Introduction  
 
The Warburg effect and Crabtree effect: cardiolipin in vitro  
 As stated in Chapter one, Kiebish et al. observed that mitochondria isolated from 
brain tumors in vivo had an abnormal cardiolipin profile that was associated with 
significant reductions in ETC activity, thus providing a structural basis for the Warburg 
effect (4). CL, a phospholipid found primarily in the inner mitochondrial membrane of 
mammalian cells, contains two phosphate head groups, three glycerol moieties, and four 
fatty acyl chains (Figure 6). CL is involved in maintaining mitochondrial function and 
membrane integrity (Figure 7). CL binds complexes I, III, IV, V and the supercomplexes 
I/III/IV and II/III/IV of the ETC and is essential for their catalytic activity (22, 23) 
(Figure 7). CL also serves as a “proton sink” by restricting protons within its head group 
domain, thus functioning to maintain the mitochondrial proton gradient and provide 
protons for ATP synthase (24, 25). Both CL content and fatty acid composition have been 
directly linked to the activities of the respiratory enzyme complexes (22, 25–27). A loss 
of CL content or alterations in its acyl chain composition have been associated with 
mitochondrial dysfunction in many tissues and several pathological conditions including 
Barth syndrome, ischemia, hypothyroidism, aging, heart failure, and brain cancer (4, 28, 
29).  
CL is synthesized through the condensation of phosphatidylglycerol (PG) and 
CDP-diacylglycerol to produce immature cardiolipin molecules that contain short-chain 
saturated fatty acid chains. Immature CL is then remodeled to mature CL by lipases, 
acyltranferases, and transacylases, which remove and transfer long-chain unsaturated 
fatty acids from choline and ethanolamine glycerophospholipids to the CL molecule (30). 
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A mature, long-chain, unsaturated CL fatty acid profile is associated with higher 
respiratory chain complex activity, while an immature, short-chain, saturated CL fatty 
acid profile is associated with low respiratory chain complex activity (4, 29, 31). Barth 
Syndrome (BTHS) is one of the best examples of the importance of CL remodeling 
within metabolic diseases. Barth syndrome is an X-linked recessive disorder 
characterized by cardiomyopathy, skeletal myopathy, growth retardation, and neutropenia 
(32). BTHS is caused by mutations in the tafazzin (TAZ) gene, which encodes an 
acyltransferase involved in the remodeling of CL. Cells from patients with BTHS contain 
decreased CL content, reduced incorporation of lineoleic acid (18:2) into CL, as well as 
decreased levels of the CL precursor PG (31, 32). Furthermore, patients affected with 
Barth syndrome showed respiratory abnormalities in isolated skeletal muscle including 
diminished concentrations of cytochromes c1 + c, b, and aa3 compared to control skeletal 
muscle mitochondria (32).  
In cancer tissues, Kiebish et al. showed in vivo that mitochondria isolated from 
several brain tumors had an abnormal and immature CL fatty acid profile compared to the 
mature CL profile of mitochondria isolated from normal synergistic host brain tissue (4). 
However, in vitro, mitochondria isolated from brain tumor cell lines, such as the VM-M3 
cell line, and non-tumorigenic cultured astrocytes both displayed abnormal and immature 
CL profiles. It was expected that the non-tumorigenic astrocytes would display a mature 
CL profile similar to the normal synergistic host brain tissue. This discrepancy between 
the CL composition of non-tumorigenic cells in vitro and in vivo may result from the in 
vitro Crabtree effect. The suppression of respiration by glucose may result in changes to 
the content and composition of the CL molecule. However, the Crabtree effect may also 
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be responsible for the immature CL profile of the tumorigenic cell lines in vitro. 
Tumorigenic cells have also been shown to display the Crabtree effect.  
 The present study examined how the in vitro growth environment could influence 
the content and composition of CL in the tumorigenic and highly metastatic VM-M3 cell 
line. It was hypothesized that CL content in the no glucose condition would be greater 
than that of the glucose condition. Glucose represses respiration and a low respiration is 
associated with low CL content. It was further hypothesized that VM-M3 cells incubated 
in no glucose media would contain CL molecules with a greater amount of longer-chain 
unsaturated fatty acids. Such CL molecules would support the higher respiration of VM-
M3 cells in the no glucose condition compared to the glucose condition.  
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Materials and Methods 
 
Reagents  
HPLC grade chloroform and methanol were purchased from Sigma-Aldrich (St. Louis, 
MO, USA). 
 
Cell Lines and Culture Conditions  
The VM-M3 cell line was previously established from the flank-grown 
spontaneous VM-M3 tumor isolated from the cerebellum of a VM/Dk strain mouse (33). 
The cells were maintained in Dulbecco’s Modified Eagle’s Medium (DMEM, Sigma, St. 
Louis, MO) with high glucose (25mM) and supplemented with 10% fetal bovine serum 
(FBS, Sigma) and 50µg/ml penicillin-streptomycin (Sigma), and phenol red (Sigma) 
(DMEM complete media). The cells were maintained in a humidified incubator at 
37ºC/5% CO2/95% air.  
 
Measurement of Oxygen Consumption and Extracellular Acidification in VM-M3 
Cells 
 
OCR and ECAR measurements were determined using the Seahorse XF96 
Extracellular Flux Analyzer. All steps in the preparation of the assay were performed at 
Boston College and the Seahorse assay was performed at Berg (Framingham, MA).  
VM-M3 cells were platted in XF96 cell culture plates (Seahorse Bioscience, 
North Billerica, MA, USA) at near confluence. The cells were incubated for 12 hours in 
DMEM complete media. The medium was then changed to the appropriate Seahorse 
media containing no sodium bicarbonate or phenol red: 
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Glucose Seahorse Media No Glucose Seahorse Media 
DMEM DMEM 
10mM glucose  0mM glucose 
2 mM glutamine 2 mM glutamine  
0.5 mg/mL Albumax I 0.5 mg/mL Albumax I 
5 mM HEPES 5 mM HEPES 
50 µg/mL penicillin-streptomycin 50 µg/mL penicillin-streptomycin 
 
VM-M3 cells were incubated in the absence of CO2 for 3 h in their respective medium. 
The medium was changed to glucose seahorse medium directly before inserting the assay 
into the Seahorse XF96 Extracellular Analyzer. The XF analyzer was programmed to 
take 7-min measurements with a 1-min mix and 1-min equilibration period before each 
measurement.  
 
 
VM-M3 Cell Growth Conditions for Lipid Analysis  
 VM-M3 cells were incubated in media containing glucose media or no glucose 
media for 4 h (media composition below). In contrast to the above Seahorse media, 
sodium bicarbonate was included since the cells were incubated in the presence of CO2. 
The cells were washed 3x with dPBS and counted using a TC20 automated cell counter. 
Cell pellets were frozen at -80°C for 1 h and then lyophilized overnight for 16 hours.  
Glucose Media No Glucose Media 
DMEM DMEM 
10mM Glucose 0mM 
2 mM Glutamine 2 mM Glutamine 
0.5mg/mL Albumax I 0.5mg/mL Albumax I 
Sodium Bicarbonate  Sodium Bicarbonate 
50 µg/ml penicillin-streptomycin 50 µg/ml penicillin-streptomycin 
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Lipid isolation 
 Total lipids were isolated and purified from lyophilized cell pellets. Total lipids 
were extracted with 5 mL of CHCl3 and CH3OH (1:1, v/v) and 0.5 mL of dH2O. The 
solution was briefly sonicated and then centrifuged for 10 min at 1,200 x g. The 
supernatant containing the total lipids was removed and the cell pellet was washed with 2 
mL of CHCl3/CH3OH (1:1, v/v). The combined supernatants were converted to a 
CHCl3/CH3OH/dH2O ratio of 30:60:8 (solvent A) through adding 2.5 mL of CHCl3, 8.5 
mL of CH3OH, and 1.6 mL of dH2O.  
 
Column chromatography  
The separation of neutral and acidic lipids was performed using DEAE-Sephadex 
(A-25; Pharmacia Biotech, Uppsala, Sweden) column chromatography as previously 
described (34). DEAE-Sephadex was prepared by washing the resin three times with 
solvent B (CHCl3/CH3OH/0.8 M Na+ acetate, 30:60:8, v/v), equilibrating in solvent A 
overnight, followed by washing three times with solvent A. The total lipid extract, which 
was suspended in solvent A, was applied to a DEAE-Sephadex column that has been 
equilibrated with solvent A. The column was washed twice with 20 mL of solvent A, and 
the neutral lipids, consisting of the initial eluate from the column and washes, were 
collected. Total acidic lipids were then eluted from the column using 40 mL Solvent B.  
 
Acidic lipid purification  
The total acidic lipid fraction was dried by rotary evaporation and separated into 
acidic lipids and gangliosides by the Folch partitioning procedure as described previously 
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(35, 36). The lower organic phase, containing the acidic lipids: cardiolipin, 
phosphatidylserine, phosphatidylinositol, phosphatidic acid, sulfatides, and free fatty 
acids, was dried under nitrogen and re-suspended in 1 mL CHCl3:CH3OH 1:1 (v/v). 
 
High-performance thin-layer chromatography  
 Acidic lipids were qualitatively analyzed using high-performance thin-layer 
chromatography (HPTLC) with modifications as previously described (34) (36). Acidic 
lipids were spotted on 10 x 10 cm silica gel 60 HPTLC plates using the Camag Linomat 
V auto-TLC spotter (Camag Scientific Inc., Wilmington, NC, USA). The amount of 
acidic lipids spotted on the HPTLC plate was equivalent to that from 2 x 106 VM-M3 
cells. An internal standard (oleyl alcohol) was added to the acidic lipid samples as a 
control for the amount of lipids spotted. Acidic lipid standards were purchased from 
Matreya and Sigma (Pleasant Gap, PA; St. Louis, MO). The cardiolipin standard (Sigma 
C-0563) is isolated from the cardiolipin of bovine heart and has a composition of >80% 
linoleic acid (18:2). The acidic HPTLC plate was developed and visualized as described 
previously (36).  
 
Gas chromatography: cardiolipin fatty acid analysis 
Preparative high performance thin-layer chromatography (20 X 20 cm) was used 
to separate CL from the other acidic lipids in VM-M3 cells. A CL standard (Sigma) was 
used to identify the CL bands in the cell samples. CL was visualized by spraying the 
HPTLC plate with a 5% primulin solution (80:20 acetone: water vol/vol) and exposure to 
Ultraviolet Light. The CL band was then scraped from the HPTLC plate, 10µg of 
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heptadecanoic acid (17:0) internal standard was added, and the solution was 
transesterified with acetyl chloride in methanol (50:1 vol/vol) for 45 min in a sealed 
borosilicate tube under nitrogen at 85° C. The samples were cooled on ice and a 6 % 
potassium carbonate solution in dH2O (6:94 vol/vol) was added to quench the 
transesterification reaction. Fatty acid methyl esters were separated from this solution 
using hexane. A gas chromatograph (HP 6890) equipped with flame ionization detector 
and split less injector was used for the analysis of CL fatty acid methyl esters. The fatty 
acids were resolved using a 30 m X 0.25mm X 0.25µM Omegawax 250 fused silica 
capillary column (Supelco). The temperature program was set to ramp from 150° to 220° 
C at 4° C per minute and was held constant at 220° C for 20 min. The flow rate was set to 
0.5 mL/min.  
 
Mass spectrometry (MS) analysis 
Lipid extraction using a modified Bligh and Dyer procedure and mass 
spectrometry analysis of CL fatty acid composition in VM-M3 cells was performed by 
Berg, LLC in Framingham, MA (37). MS analysis was performed using an Ab Sciex 
TripleTOF System.  
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Results  
 
Oxygen consumption rate and extracellular acidification rate of VM-M3 cells in 
glucose and no glucose media  
 
 The VM-M3 cells line, established in Dr. Seyfried’s laboratory from a 
spontaneous brain tumor, was previously used by Kiebish et al. for analysis of CL 
content and composition in vivo and in vitro (38, 39). However, analysis of both the 
tumorigenic VM-M3 cell line and non-tumorigenic astrocytes displayed an immature CL 
profile in vitro. It was expected that the non-tumorigenic cell line would display a mature 
CL profile in vitro similar to non-tumorigenic brain tissue in vivo. The immature CL 
profile of the astrocytes in vitro may result from the Crabtree effect. In addition, the 
immature CL profile of the tumorigenic VM-M3 cell line may also be influenced by the 
Crabtree effect. Therefore, this study examined the possible influence of the Crabtree 
effect on the immature CL profile of the tumorigenic VM-M3 cells line in vitro.  
The VM-M3 cells display a robust Crabtree effect in vitro (Figure 5). The oxygen 
consumption rate (OCR) of cells incubated in glucose media for 2 h was significantly 
lower than the OCR of cells grown in no glucose media. In addition, the extracellular 
acidification rate (ECAR) of VM-M3 cells grown in glucose media was significantly 
higher than the ECAR of cells incubated in no glucose media (Figure 5).  
 
Acidic lipid profile of VM-M3 cells in glucose and no glucose growth conditions 
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The CL content of VM-M3 cells grown in glucose media for 4 h was not 
significantly different from the CL content of VM-M3 cells grown in no glucose for 4 h 
(Figure 8; Table I). However, the content of phosphatidylglycerol (PG) was significantly 
decreased in the no glucose condition compared to the glucose condition (Figure 8; Table 
1). No other acidic lipids analyzed were significantly different in their content between 
VM-M3 cells incubated in glucose and VM-M3 cells incubated in no glucose media 
(Figure 8; Table 1).  
 
Cardiolipin composition of VM-M3 cells in glucose and no glucose growth 
conditions: gas chromatography (GC) 
 
 Since VM-M3 cells grown in glucose and no glucose media for 4 h did not 
display a significant difference in CL content, the fatty acid compositions of the CL 
molecules were analyzed by GC. Palmitoleic Acid (C16:1) was the only fatty acid species 
in the VM-M3 cells that had a significantly higher percent composition in the no glucose 
condition compared to the glucose condition (Table II). The ratio of monounsaturated 
fatty acids (MUFA: C16:1 and C18:1) to polyunsaturated fatty acids (PUFA: C18:2n-6, 
C18:3, C20:3, and C20:4n-6) was not significantly different between the glucose and no 
glucose conditions (Table II). However, the ratio of short chain fatty acid species (SCFA: 
C16-18) to long chain fatty acid species (LCFA: C20) was significantly higher in the 
glucose condition compared to the no glucose condition. The percentage of longer chain 
fatty acids was therefore higher in the no glucose condition compared to the glucose 
condition.  
A trend toward a greater long-chain unsaturated fatty acid composition of VM-
M3 cells grown in no glucose media compared to VM-M3 cells grown in glucose media 
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was observed. Increasing the time of incubation in glucose and no glucose media past 4 h 
may result in a significantly greater percent composition of longer unsaturated fatty acid 
species in the no glucose condition compared to the glucose condition. The kinetics of 
CL remodeling in the VM-M3 cells under the conditions analyzed has not been analyzed.  
 
Cardiolipin composition of VM-M3 Cells in glucose and no glucose growth 
conditions: MS  
 
 Mass Spectrometry was also used as a more sensitive and powerful means of 
analyzing the differences in fatty acid composition of VM-M3 cells grown in glucose and 
no glucose conditions for 4 hours. The CL lipodome displays that, overall, VM-M3 cells 
incubated in no glucose media (blue) contain a greater amount of longer-chain, 
unsaturated CL molecular species compared to VM-M3 cells incubated in glucose media 
(red) (Figure 9). However, a limited number of CL molecular species were significantly 
different between VM-M3 cells grown in glucose media and no glucose media (Figure 9). 
Therefore, increasing the limited sample size in these conditions may result in a more 
statistically significant difference in CL composition between the two conditions studied. 
Furthermore, modulating the time the cells are incubated in each condition may also 
influence the CL profile depending on the turnover rate of CL fatty acid species in these 
specific conditions.   
 
Proliferation of VM-M3 cells in glucose and no glucose condition  
 
 There was no significant difference in the proliferation or observed morphology 
of VM-M3 cells grown in 10 mM glucose and no glucose conditions for 4 h (Figure 10).  
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Discussion  
 
In addition to the RAW and BV-2 macrophage cells, the VM-M3 cells also 
displayed a robust Crabtree effect in vitro. However, the assessment of the VM-M3 
Crabtree effect was not performed in real-time.  
As an extension of the effect of glucose and no glucose conditions on oxygen 
consumption and extracellular acidification rates of the VM-M3 cells, the underlying 
structural differences that may exist between these two culture conditions were also 
studied. Such structural changes included the content and composition of the 
phospholipid cardiolipin. CL is highly enriched in the inner mitochondrial membrane and 
provides structure to the complexes of the electron transport chain. The content and fatty 
acyl composition of CL have been directly linked to the activities of the respiratory 
enzyme complexes (22, 25–27). Greater CL content and longer-chain unsaturated CL 
molecular species have been associated with higher respiration (4, 29, 31). Therefore, 
since the respiration of VM-M3 cells increased in no glucose media compared to glucose 
(10 mM) media, it was expected that the CL content would increase and the CL 
molecules would contain longer and unsaturated fatty acyl chains in VM-M3 cells 
incubated in no glucose media compared to glucose media. Although the content of CL 
did not significantly change when VM-M3 cells were incubated in glucose (10 mM) and 
no glucose media for 4 h, the molecular species of CL did change significantly. Gas 
chromatography analysis of the CL fatty acid species showed that VM-M3 cells grown in 
no glucose media for four hours had a significantly greater percent composition of 
palmitoleic acid (C16:1) and a lower SCFA/ LCFA ratio compared to the glucose 
condition. Although not robust, these changes support previous studies showing that CL 
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fatty acid species are more saturated and have longer chain lengths in cells with a high 
respiration (4, 29, 31). These changes in fatty acid composition also display a dynamic 
nature of CL remodeling in response to different energy substrates in vitro.  
A more robust change in CL composition between VM-M3 cells incubated in 
glucose and no glucose for four hours was observed using a more sensitive MS analysis 
of CL molecular species. The CL lipidome of VM-M3 cells incubated in no glucose 
media, overall, contained a longer-chain and more unsaturated fatty acid profile 
compared to VM-M3 cells incubated in glucose media. This data further supports the 
association of higher respiration with a longer-chain unsaturated CL molecular species 
profile and the dynamic CL remodeling that occurs when VM-M3 cells, grown 
previously in glucose media, are incubated in media lacking glucose.  
The number of VM-M3 cells incubated in media devoid of glucose for 4 h was 
not statistically significant from VM-M3 cells grown in 10 mM glucose media. This 
suggests that the absence of glucose had no affect on cell viability over the course of a 4 
h incubation period. Therefore, the changes in CL molecular species detected by both GC 
and MS were not a result of a change in proliferation rate.  
However, a long-term growth analysis of VM-M3 cells in glucose media and low 
glucose media showed large differences in the growth potential of VM-M3 cells in low, 
0.05mM glucose and 10mM glucose media. VM-M3 cells in low glucose media did not 
proliferate over a seven-day time period, while VM-M3 cells in glucose media displayed 
high proliferation (data not shown). When the VM-M3 cells in low glucose media were 
transitioned to 10mM galactose media, the cells proliferated slowly. VM-M3 cell number 
generally doubled over the seven-day period in galactose media. Similar results were 
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seen in HeLa cells (14). HeLa cells grown in galactose media had a significantly higher 
doubling time than HeLa cells grown in glucose media (14). The slower growth or 
absence of growth of VM-M3 cells in low glucose and galactose media shows that VM-
M3 cells cannot support a high proliferation in vitro without a large concentration of 
glucose. Just as cancer cells preferentially utilize glucose for growth in vivo, VM-M3 
tumor cells require glucose in vitro in order to sustain a high proliferation. Furthermore, 
the changes in VM-M3 proliferation rate and viability must also be considered when 
analyzing the CL content and composition in glucose and no glucose conditions for more 
than 4 h.  
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Figure 5. Oxygen consumption rate and extracellular acidification rate of VM-M3 
cells. A. The oxygen consumption rate (OCR) of VM-M3 cells incubated for 2 hours in 
glucose and no glucose media was recorded using the Seahorse XF96 Flux analyzer. 
Results are presented as the mean nanomoles of O2 consumed per hour per mg protein ± 
Standard Deviation (SD). B. The extracellular acidification rate (ECAR) of VM-M3 cells 
incubated for 2 h in glucose and no glucose media was recorded using the Seahorse XF96 
Flux analyzer. Results are presented as the mean milli-pH per hour per mg protein ± 
standard deviation (SD). n=8 for both the glucose and no glucose conditions. ** indicates 
p < 0.01.  
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Figure 6. The structure of cardiolipin (CL).  Tetralinoleoyl cardiolipin is one of several 
species of CL found in the VM-M3 cells. Adapted from LIPID MAPS Lipidomics 
Gateway.  
Common name: CL(1'[18:2(9Z,12Z)/18:2(9Z,12Z)],3'[18:2(9Z,12Z)/18:2(9Z,12Z)])  
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Figure 7. The association of cardiolipin (CL) with the electron transport chain 
(ETC). The enzymes associated with oxidative phosphorylation (OXPHOS) and ATP 
synthesis are located in the inner mitochondrial membrane of eukaryotes. The electrons 
that are delivered to complex I or II of the ETC are transferred by the lipid-soluble carrier 
ubiquinone (Q), complex III, and cytochrome c (cyt c) to complex IV. The electrons are 
then transferred to molecular oxygen producing H2O. Complexes I, III, and IV pump 
protons from the mitochondrial matrix into the intermembrane space (IMS) thus creating 
a pH gradient and establishing a membrane potential. The pH gradient is used by ATP-
synthase (complex V) to synthesize ATP from ADP and organic phosphate. All of the 
enzymes of the ETC are bound to or associated with CL. The electron carrier cytochrome 
c has also been shown to be associated with CL. Abbreviations: OM: outer mitochondrial 
membrane; IMS: mitochondrial intermembrane space; IM: inner mitochondrial 
membrane. Adapted from R.K. Houtkooper and F.M. Vaz, 2008 (40).  
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Figure 8. High performance thin-layer chromatogram (HPTLC) of acidic lipids in 
VM-M3 cells grown in the presence (Glc +) and absence (Glc −) of 10mM glucose 
for 4 hours. Three individual VM-M3 cell populations grown in 10mM glucose (Glc +) 
and 0mM glucose (Glc −) were analyzed. The abbreviations used are as follows: O, 
origin; PS, phosphatidylserine; PI, phosphatidylinositol; PG, phosphatidylglycerol; PA, 
phosphatidic acid; CL, cardiolipin; IS, internal standard (oleyl alcohol); FFA, free fatty 
acid; and SF, solvent front of the first developing solvent system.  
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Table I– Acidic lipid distribution of VM-M3 cells cultured in the presence and absence of glucose 
Acidic Lipidsb 
VM-M3 Cells 
Glc +a Glc −a 
Cardiolipin (CL) 2.9 ± 0.3 3.2 ± 0.2 
Phosphatidic acid (PA)  1.5 ± 0.2 1.7 ± 0.2 
Phosphatidylglycerol (PG) 0.5 ± 0.1 0.3 ± 0.1* 
Phosphatidylserine (PS) 4.9 ± 0.4 5.0 ± 0.4 
Phosphatidylinositol (PI)  5.1 ± 0.4 4.3 ± 0.3 
a Values are expressed as the mean ± SD (n = 3 independent samples) 
b Determined from densitometric scanning of HPTLC as shown in Fig. 1; values are expressed as µg lipid/ 2 
million cells 
* Indicates statistical significance between VM-M3 cells cultured in DMEM supplemented with 10mM 
glucose (Glc +) and VM-M3 cells cultured in DMEM without glucose (Glc -) at p < 0.05 as determined by an 
independent samples t-test  
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Table II- Fatty acid composition of cardiolipin in VM-M3 
 cells cultured in the prescence and absence of glucose  
  
FAME 
VM-M3 Cells 
Glc + Glc - 
    
  
  C16:0 10.9 ± 1.8 10.0 ± 2.0 
C16:1 2.2 ± 0.7 3.9 ± 0.8* 
C18:0 10.0 ± 0.5 10.7 ± 1.7 
C18:1 54.5 ± 4.8 49.2 ± 1.6 
C18:2n-6 17.4 ± 1.3 16.8 ± 2.5 
C18:3 4.0 ± 0.9 3.4 ± 1.3 
C20:3 1.8 ± 0.4 2.8 ± 1.5 
C20:4n-6 4.9 ± 0.7 6.0 ± 0.5 
MUFA/PUFAa 2.0 ± 0.1 1.8 ± 0.1 
SCFA/LCFAb 14.8 ± 1.8 10.6 ± 1.8* 
Values are expressed as the mean mole percent distribution of fatty acid 
methyl ester ± SD (n = 3) 
     * Indicates significance of VM-M3 cells incubated in glucose media from 
no glucose media at p < 0.05 
    a MUFA represents C16:1, C18:1. PUFA represents C18:2n-6, C18:3, 
 C20:3, C20:4n-6 ; p = 0.071 
    bSCFA (shorter chain fatty acids: C16-C18).  
  LCFA (longer chain fatty acids: C20) 
   
       !
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Figure 9. Cardiolipin lipidome of VM-M3 cells cultured in 10 mM glucose (+ 
glucose) and no glucose (− glucose) conditions for 4 h. The graph is organized so that 
the length and saturation of the CL fatty acid species increases from left to right. 
Therefore, shorter-chain saturated fatty acid species are on the left side of the graph, 
while longer-chain unsaturated fatty acid species are on the right side of the graph. Data 
is displayed as the moles of CL/ mg protein. n=3 independent samples for each condition. 
Yellow stars indicate a significant difference in the content of the CL fatty acid species 
indicated between the glucose and no glucose condition at p > 0.05. 
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Figure 10. Proliferation of VM-M3 cells grown in the presence (Glc +) and absence 
(Glc −) of 10 mM glucose for 4 h. VM-M3 cells were cultured in DMEM media 
containing 10mM glucose or 0mM glucose for 4 h. The individual cell populations were 
analyzed for both conditions (n=3). After 4 h, the VM-M3 cells were counted using a 
TC20 Automated Cell Counter. Cell numbers are expressed as the mean cell number ± 
SD.  
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CHAPTER 3 
 
METABOLISM OF ACTIVATED MACROPHAGES  
 
Link to Previous Chapter: Chapter 1 focused on the in vitro mitochondrial energy 
metabolism of the RAW macrophage cell line and BV-2 microglia cell line under non-
activated conditions. Therefore, this study aimed to analyze the effect of macrophage 
activation on the energy metabolism of RAW and BV-2 cells.  
 
Background: It has been previously shown that immune cells change their core 
metabolism from oxidative phosphorylation to glycolysis upon activation. Underlying 
this change in metabolism is the production of the metabolite nitric oxide (NO). NO has 
been shown to inhibit cytochrome c oxidase activity resulting in the stabilization of HIF-
1α and activation of glycolysis.  
 
Methodology and Principle Observations: The effect of LPS-activation on the 
respiration of RAW and BV-2 cells was analyzed using the Seahorse XF96 instrument. 
LPS-activation significantly decreased the respiration of both RAW and BV-2 cells in a 
concentration dependent manner. This decrease in respiration is seemingly modulated in 
part by NO production. The scavenging of NO with L-NAME significantly increased the 
respiration of RAW cells, but had no effect on the respiration of BV-2 cells at a 
concentration of 1µM. Overall, the BV-2 cells did not respond as robustly to LPS 
activation or L-NAME treatment compared to the RAW cells. A diminished response to 
LPS activation has previously been characterized in BV-2 cells in comparison to primary 
murine microglia (PM) cells (19).  
 
Conclusions and Significance: Both RAW and BV-2 cells display a concentration 
dependent decrease in OCR and increase in ECAR following LPS-activation. 
Furthermore, the immediate increase in OCR and decrease in ECAR following treatment 
of LPS-activated cells with the iNOS inhibitor L-NAME suggests that the OCR and 
ECAR of LPS-activated cells are mediated in by nitric oxide and are reversible in real-
time.  
 
Interestingly, the Warburg effect that is observed upon LPS-activation of RAW and BV-2 
cells is concomitant with a decrease in cell proliferation. Whereas, cancer cells typically 
display a Warburg effect with a concomitant increase in cell proliferation.  
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Introduction: The Warburg effect and activated macrophages 
 
I. The Warburg effect and activated immune cells  
 As stated previously, Warburg observed that in the presence of oxygen tumor 
cells consume less oxygen and more glucose than normal untransformed cells (1–3). The 
reduced oxygen consumption of cancer cells that Warburg observed was concomitant 
with an increase in lactate fermentation (glycolysis) (1–3). This observation has been 
termed “aerobic glycolysis” or the “Warburg effect.” In 1970, G.C. Hard showed that a 
similar change in metabolism was evidenced in activated murine peritoneal macrophages, 
which had lower levels of oxygen consumption and higher levels of lactate production 
compared to resting macrophages (41). This study provided the first evidence of the 
metabolic change that occurs in macrophages following activation. Recently, the change 
in core metabolism from oxidative phosphorylation to glycolysis in activated monocytes, 
macrophages, dendritic cells, and T cells has been increasingly studied (Figure 7) (42–
44). Specifically, Tannahil et al. showed that bone marrow-derived macrophages 
(BMDMs) activated by the gram negative bacterial product lipopolysaccharide (LPS) 
change their metabolism from oxidative phosphorylation to glycolysis (43). The LPS 
activated macrophages showed an up-regulation of glycolytic and down-regulation of 
mitochondrial genes and metabolites in addition to an increase in the TCA cycle 
intermediate succinate (43). Succinate was produced primarily through glutamine-
dependent anerplerosis with the contribution of the agmma-aminobutyric Acid (GABA)-
shunt. This increase in succinate resulted in the stabilization of hypoxia-inducible factor 
1α (HIF-1α), which induced interleukin 1β (IL-1β) production.  
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II. Activated macrophages and nitric oxide (NO) production  
The activation of macrophages results in a change in metabolism from oxidative 
phosphorylation to glycolysis. This metabolic change in activated macrophages is 
accompanied by the induction of inducible NO synthase (iNOS) and the generation of 
nitric oxide (NO), a molecule that inhibits cellular respiration (45). NO, produced from 
L-arginine by iNOS, reversibly inhibits cytochrome c oxidase in competition with 
oxygen, which results in the stabilization of HIF-1α and activation of glycolysis (45, 46). 
The production of NO, a lipid- and water-soluble radical gas, is a principle cytotoxic 
mechanism of activated macrophages.  
In order to study the effects of NO on the OCR and ECAR, NO production may 
be competitively inhibited by the L-arginine analog N-nitro-L-arginine methyl ester (L-
NAME).  
In the present study, the effect of different concentrations of LPS on the oxygen 
consumption rate and extracellular acidification rate was evaluated in RAW and BV-2 
macrophage cell lines. The effect of L-NAME, an iNOS inhibitor, on the oxygen 
consumption rate and extracellular acidification rate was studied in real-time.  
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Materials and Methods  
 
Reagents  
Lipopolysaccharide (LPS) and the L-arginine analog N-nitro-L-arginine methyl 
ester (L-NAME) were obtained from Sigma-Aldrich (St. Louis, MO, USA).  
 
Measurement of Oxygen Consumption and Extracellular Acidification Rates of 
RAW and BV-2 Cells  
 
OCR and ECAR measurements were obtained using the Seahorse XF96 
Extracellular Flux Analyzer. All steps in the preparation of the assay were performed at 
Boston College and the Seahorse assay was performed at Berg, LLC (Framingham, MA).  
BV-2 and RAW246.7 cells were seeded at near confluence in Seahorse 96 well 
culture plates. The cells were allowed to seed for three hours in DMEM complete media 
(See Chapter 1 Materials and Methods for its composition). The media was then changed 
and the cells were incubated for 12 h in DMEM complete media with no LPS, or 1, 10, or 
100 ng/mL LPS. The media was than changed to glucose seahorse media (See Chapter 1 
Materials and Methods for composition) and incubated in a non-CO2 incubator for 2 h 
before the assay was inserted into the Seahorse XF96 analyzer. The XF analyzer was 
programmed to take 2-minute measurements with a 1-min mix and 2-min equilibration 
period before each measurement. 1mM L-NAME in glucose seahorse media was injected 
into the assay through drug port A when indicated.  
 
RAW264.7 cell growth assay  
The growth of RAW cells was assessed by dry weight. An initial dry-weight of 
the 30 million cells seeded was determined. 30 million RAW cells were washed 3X with 
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PBS, incubated at -80°C for 1 hour, and then lyophilized overnight for 18 h before being 
weighed.  
30 million RAW cells were seeded in 150mm dishes in DMEM media containing 
10% FBS for 3 h. The cells were then washed 3X with PBS and incubated in 10 mM 
glucose media with or without 50 ng/mL LPS for 72 hours. The RAW cells were then 
scraped, washed 3X with PBS, and the cell pellets were incubated at -80°C for 1 hour. 
The cell pellets were then lyophilized overnight for 18 h and the final dry-weight was 
determined.  
 
Statistics  
Statistical analyses were performed on all data using IBM SPSS 21 Statistics 
Software. Two-tailed t-tests were performed and the significance values were determined 
where indicated. 	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Results 
 
OCR and ECAR of LPS-activated RAW cells  
 The OCR of RAW cells activated with 1 ng/mL (220 ± 36 pmol/min), 10ng/ml 
(134 ± 12 pmol/min), and 100 ng/mL LPS (113 ± 9 pmol/min) displayed significantly 
lower oxygen consumption rates compared to non-activated RAW cells (479 ± 19) 
(Figure 11 A,B) and showed a dose-dependent response to LPS over the range of LPS 
concentrations analyzed. RAW cells treated with 10 and 100 ng/mL LPS for 12 h had 
significantly lower OCR measurements compared to cells treated with 1 ng/mL LPS 
(Figure 11B). However, there was no significant difference in OCR between RAW cells 
treated with 10 and 100 ng/mL LPS (Figure 11B). Therefore, a maximal decrease in OCR 
is obtained between LPS concentrations of 10-100ng/ml when treated for 12 h.  
 In agreement with the significant decrease in OCR upon LPS activation, the 
ECAR of RAW cells treated with 1 ng/mL (65 ± 6 mpH/min), 10 mg/mL (68 ± 7 
mpH/min), and 100ng/ml (68 ± 3 mpH/min) LPS significantly increased in each of these 
conditions compared to the non-activated RAW cells (34 ± 3mpH/min) (Figure 12A,B). 
However, a dose-dependent response in the OCR of RAW cells to LPS was not 
evidenced in the ECAR data (Figure 12B). The ECAR values of RAW cells treated with 
1, 10, and 100ng/ml LPS were not significantly different from each other (Figure 12B).  
 The activation of RAW cells with LPS causes the cells to release nitric oxide 
(NO), which is a known inhibitor of respiration. In order to study the reversibility of the 
inhibition of respiration by NO, L-NAME, an L-arginine analog that competitively 
inhibits the production of NO, was used. The effect of NO on the inhibition of respiration 
was analyzed in real-time using the injection ports on the XF96 Seahorse Extracellular 
	  60	  
Flux Analyzer. Glucose seahorse media containing 4uM of L-NAME was injected 
through each port in order to obtain a final L-NAME concentration of 1 µM for each 
condition in the assay. In order to insure that any changes in OCR or ECAR were the 
result of L-NAME and not an increase in media volume, both activated (1,10, and 100 
ng/mL LPS) and non-activated RAW cell conditions were injected with media containing 
no L-NAME. The addition of media did not significantly influence the OCR or ECAR in 
these conditions (data not shown).  
Following the addition of L-NAME to activated RAW cells, there was a 
significant increase in OCR and a significant decrease in ECAR (Figure 11C; 12C). 
However, the OCR values remained significantly lower than the OCR of non-activated 
RAW cells and the ECAR remained significantly higher than the ECAR of non-activated 
RAW cells (Figure 11B; 12B). Therefore, the addition of L-NAME and quenching of NO 
production did not result in the ability of the activated RAW cells to respire to the same 
degree as non-activated RAW cells. Interestingly, the addition of L-NAME to non-
activated RAW cells significantly decreased the OCR, but did not affect the ECAR 
(Figure 11C; 12C). Furthermore, after the addition of L-NAME to the RAW cells, the 
dose-dependent response of the RAW cell OCR to LPS was maintained (Figure 11B).  
 
LPS-activated RAW cell growth 
 In order to understand the effect of LPS on RAW cell proliferation, a long-term 
(72 h) growth assay was performed. An LPS concentration of 50 ng/mL was chosen to 
ensure a maximum decrease in OCR for activated RAW cells. After 72 h, the activated 
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RAW cells had a significantly lower total cell dry weight than RAW cells incubated in 
DMEM containing 10 mM glucose (Figure 13).  
 
OCR and ECAR of LPS-activated BV-2 cells  
 BV-2 cell activated with 10 ng/mL (195 ± 14 pmole/min) displayed a 
significantly lower oxygen consumption rate compared to non-activated BV-2 cells (221 
± 7 pmol/min) as well as BV-2 cells activated with 1ng/ml LPS (224 ± 7 pmol/min) 
(Figure 14A,B). There was no difference in OCR between BV-2 cells activated with 
1ng/ml LPS and non-activated BV-2 cells (Figure 14A,B).  
 Interestingly, both BV-2 cells treated with 1ng/ml LPS (24 ± 2 mpH/min) and 10 
ng/mL LPS (25 ± 2 mpH/min) had significantly higher extracellular acidification rates 
(ECAR) compared to the non-activated BV-2 cells (21± 1 mpH/min) (Figure 15A,B). 
The 1 ng/mL LPS condition thus had a significantly higher ECAR, but not a significantly 
lower OCR in the BV-2 cells.  
 Following the addition of L-NAME to the BV-2 cells, there was no significant 
difference in OCR or ECAR for both activated and non-activated BV-2 cells (Figure 
14B,C; Figure 15B,C). It was also confirmed in the BV-2 cells that the addition of L-
NAME was influencing any possible changes in OCR and ECAR and not the added 
media (Data not shown).  
 Overall, the BV-2 cells did not respond as robustly to activation by LPS or 
inhibition of nitric oxide (NO) production by L-NAME as the RAW cells (Figure 16). 
Using the OCR/ECAR ratio, RAW cells and BV-2 cells may be compared. A greater 
decrease in the OCR/ECAR ratio from the corresponding non-activated cells is seen in 
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the RAW cells activated with 10 ng/mL LPS (green) compared to the BV-2 cells 
activated with 10 ng/mL LPS (blue) (Figure 16B). Furthermore, RAW cells activated 
with 10 ng/mL LPS display a significant increase in the OCR/ECAR when L-NAME is 
added, while BV-2 cells activated with 10 ng/mL LPS display no significant change in 
the OCR/ECAR when L-NAME is added (Figure 16C). This suggests that RAW cells are 
more sensitive to a 1 µM L-NAME concentration than BV-2 cells, as assessed by the 
change in the OCR/ECAR ratio.  
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Discussion  
  
Both the RAW264.7 macrophage cell line and BV-2 microglia cell line display a 
Warburg effect when activated with LPS.  
 In RAW cells, a significant decrease in oxygen consumption rate and increase in 
extracellular acidification rate is observed when cells are activated with LPS. These data 
suggest that the respiration of LPS-activated RAW cells is lower than non-activated 
RAW cells, while the glycolytic activity is higher in LPS-activated RAW cells compared 
to non-activated RAW cells. The decrease in oxygen consumption rate and increase in 
extracellular acidification rate in RAW cells activated with LPS was concentration 
dependent. These data are similar to the findings of Tannahil et al. (43). Tannahil showed 
that bone marrow-derived macrophages (BMDMs) activated by the Gram negative 
bacterial product lipopolysaccharide (LPS) change their core metabolism from oxidative 
phosphorylation to glycolysis (43). 
The addition of L-NAME to inhibit the production of nitric oxide (NO), an 
inhibitor of respiration, significantly increased the OCR and significantly decreased the 
ECAR of RAW cells at all concentrations of LPS analyzed in real-time. This suggests 
that NO is responsible for the inhibition of respiration and increase in glycolysis seen in 
RAW cells activated with LPS. However, a 1µM concentration of NO was not sufficient 
to return the OCR and ECAR measurements of RAW cells treated with 1,10, and 100 
ng/mL LPS to the same OCR and ECAR measurements of non-activated RAW cells. The 
effect of greater concentrations of NO on both OCR and ECAR at each dose of LPS, in 
addition to the amount of NO in the culture media, must be analyzed before the effect of 
NO on LPS-activated RAW cell respiration and glycolytic activity can be fully assessed.  
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Interestingly, the addition of 1 µM L-NAME to non-activated RAW cells significantly 
decreased the OCR, but had no effect on ECAR. Therefore, the compound L-NAME may 
have an effect on RAW cell respiration in the absence of nitric oxide (NO) production.  
The growth of LPS-activated RAW cells was also found to be significantly lower 
than non-activated cells. Since the maximal decrease in respiration of LPS-activated 
RAW cells is between 10 and 100 ng/mL LPS, a 50ng/mL LPS concentration was used 
for the 72 h growth analysis of activated and non-activated RAW cells. The slower 
growth of LPS-activated RAW compared to non-activated RAW cells shows that 
activated RAW cells demonstrate a Warburg effect without the concomitant high 
proliferation seen in most cancer cells in vitro.  
In BV-2 cells, a significant decrease in oxygen consumption rate is observed only 
when cells are activated with 10 ng/mL LPS. Whereas, a significant increase in the 
extracellular acidification rate is observed in BV-2 cells activated with both 1 and 10 
ng/mL LPS. Furthermore, BV-2 cells did not respond to the addition of L-NAME. 
Therefore, BV-2 cells do not appear to be as responsive to LPS-activation as RAW264.7 
cells. Comparisons between RAW and BV-2 cells using the OCR/ECAR ratio further 
elucidate the seemingly higher response of RAW cells to LPS activation and NO 
production inhibition with L-NAME, as assessed by OCR and ECAR measurements. A 
weaker response to LPS activation has also been characterized in BV-2 cells in 
comparison to primary murine microglia (PM) cells (19). BV-2 cells displayed an overall 
lower expression profile of genes associated with inflammation compared to primary 
murine microglia (19). Therefore, BV-2 cells may have a high basal activation state 
which would weaken the response of BV-2 cells to LPS activation.  This may explain 
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why BV-2 cells did not display as robust of a response in OCR and ECAR to LPS 
activation and NO inhibition with L-NAME as the RAW264.7 cells.   
In summary and in agreement with previous studies, the data suggest that both 
RAW264.6 and BV-2 cells change their core metabolism from oxidative phosphorylation 
to glycolysis upon LPS-activation in vitro. This change in metabolism in the RAW264.7 
cells is mediated in part by the production of nitric oxide (NO). Interestingly, the data 
suggest that the BV-2 cells are already activated without the addition of LPS (high basal 
activation state). Therefore, the suitability of BV-2 cells as a non-activated macrophage 
control cell line must be questioned. This is especially important when conducting studies 
on the metabolism of BV-2 cells in their non-activated state, as a suppression of oxygen 
consumption may result from their basal activation and production of NO, a respiratory 
inhibitor.  
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Figure 11. Oxygen consumption rate (OCR) of RAW264.7 cells treated with LPS 
and L-NAME. RAW264.7 cells were treated with 1, 10, and 100 µg/mL LPS in 
Seahorse media for 12 hours before initiating OCR measurements using the XF96 
Extracellular Flux Analyzer. Basal OCR measurements were obtained before adding 25 
µl of 4 µM L-NAME media at 16 min to each condition to obtain a final L-NAME 
concentration of 1 µM. All data points in the assay are presented in (A) as the mean OCR 
± S.D. OCR measurements from the data point before the addition of L-NAME and the 
data point after the addition of L-NAME are presented in bar graph format as the mean 
OCR ± S.D. for each condition (B). The effect of L-NAME on the OCR for each 
condition is depicted in (C) and expressed as the mean OCR ± S.D. In each condition n = 
12. * indicates p < 0.05 compared to the No LPS condition or condition indicated and § 
indicates p < 0.05 compared to 1ng/ml LPS. 
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Figure 12. Extracellular acidification rate (ECAR) of RAW264.7 cells treated with 
LPS and L-NAME. RAW264.7 cells were treated with 1, 10, and 100 µg/mL LPS in 
Seahorse media for 12 hours before initiating ECAR measurements using the XF96 
Extracellular Flux Analyzer. Basal ECAR measurements were obtained before adding 25 
µl of 4 µM L-NAME media at 16 min to each condition to obtain a final L-NAME 
concentration of 1 µM. All data points in the assay are presented in (A) as the mean 
ECAR ± S.D. ECAR measurements from the data point before the addition of L-NAME 
and the data point after the addition of L-NAME are presented in bar graph format as the 
mean ECAR ± S.D. for each condition (B). The effect of L-NAME on the ECAR for each 
LPS concentration analyzed is depicted in (C) and expressed as the mean ECAR ± S.D. 
In each condition n = 12. * indicates p < 0.05 compared to the No LPS condition or 
condition indicated. 
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Figure 13. RAW264.7 growth in glucose (10mM) and glucose (10mM) + LPS (50 
ng/mL) media. RAW264.7 cells were treated with LPS for 72 hours. The initial and final 
dry weight of the lyophilized cell pellet was recorded. * indicates p <0.05. n = 5 
independent cell populations per group. 
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Figure 14. OCR of BV-2 cells treated with LPS and L-NAME. BV-2 cells were 
treated with 1 and 10 µg/ml in glucose media for 12 h before initiating OCR 
measurements using the XF96 Extracellular Flux Analyzer. Basal OCR measurements 
were obtained before adding 25 µl of 4 µM L-NAME media at 29 min to each cell sample 
to obtain a final L-NAME concentration of 1 µM. All data points in the assay are 
presented in (A) as the mean OCR ± S.D. OCR measurements from the data point before 
the addition of L-NAME and the data point after the addition of L-NAME are presented 
in bar graph format as the mean OCR ± S.D. for each condition (B). The effect of L-
NAME on the OCR for each LPS condition analyzed is depicted in (C) and expressed as 
the mean OCR ± S.D. n, the number of replicates for each sample was 5 or 10. * indicates 
p < 0.05 compared to the no LPS condition or condition indicated and § indicates p < 
0.05 compared to 1 ng/mL LPS condition.  
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Figure 15. Extracellular acidification rate (ECAR) of BV-2 cells treated with LPS 
and L-NAME. RAW264.7 cells were treated with 1 and 10 ug/mL LPS in glucose media 
for 12 h before initiating ECAR measurements using the XF96 Extracellular Flux 
Analyzer. Basal ECAR measurements were obtained before adding 25 µl of 4 µM L-
NAME media at 29 min to each condition to obtain a final L-NAME concentration of 1 
µM. All data points in the assay are presented in (A) as the mean ECAR ± S.D. ECAR 
measurements from the data point before the addition of L-NAME and the data point 
after the addition of L-NAME are presented in bar graph format as the mean ECAR ± 
S.D. for each condition (B). The effect of L-NAME on the ECAR for each LPS 
concentration analyzed is depicted in (C) and expressed as the mean ECAR ± S.D. Five 
or ten replicates were done for each LPS condition. * indicates p < 0.05 compared to the 
No LPS condition or condition indicated. 
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Figure 16. OCR/ECAR Ratio in non-activated and 10ng/ml LPS-activated RAW 
and BV-2 cells. All data points in the assay are presented in (A) as the mean OCR/ECAR 
± S.D. OCR/ECAR ratios from the data point before the addition of L-NAME is 
presented in bar graph format as the mean OCR/ECAR ± S.D. for each condition (B). 
The effect of L-NAME on the ECAR for the 10 ng/mL LPS concentration is depicted in 
(C) and expressed as the mean OCR/ECAR ± S.D. * indicates p < 0.05 compared to the 
no LPS condition.   
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CHAPTER 4 
 
THE IN VITRO NEUTRAL AND ACIDIC LIPID PROFILES OF RAW264.7 
CELLS IN GLUCOSE, NO GLUCOSE, AND LPS ACTIVATED CONDITIONS  
 
Link to Chapters 1 and 3: Chapters 1 and 3 studied the mitochondrial energy 
metabolism of RAW cells under in vitro conditions with glucose, without glucose, and 
LPS. This chapter presents and analyzes the neutral and acidic lipid profiles of the RAW 
cells in conditions similar to those studied above.  
 
Background: The lipid of interest in this study was cardiolipin since this lipid is 
associated with energy metabolism. CL, an acidic phospholipid localized in the inner 
mitochondrial membrane, is integral in maintaining mitochondrial function and 
membrane integrity. Both CL content and fatty acid composition have been directly 
linked to the activities of the respiratory enzyme complexes. High respiratory enzyme 
activity and oxygen consumption has been associated with high CL content, while low 
respiratory enzyme activity and oxygen consumption has been associated with low CL 
content.  
 
Methodology and Principle Observations: The neutral and acidic lipid profiles of 
RAW cells were studied following incubation in different medias for 72 h in order to 
determine long-term changes in lipid composition. Due to the long incubation period, 
fetal bovine serum was added to the medium, which resulted in the removal of the no 
glucose condition and addition of a low glucose condition. The lipid profile of RAW cells 
showed a significantly higher CL percent distribution in the low glucose condition 
compared to the glucose condition.  
 
Conclusions and Significance: Previous data showed that the level of cellular 
respiration activity is directly correlated with the level of CL content. Previous data in 
this manuscript showed that RAW cells incubated in media containing no glucose 
displayed a significantly higher oxygen consumption rate (respiration) than RAW cells 
incubated in glucose media. Therefore, RAW cells incubated in glucose media show a 
low respiratory capacity and CL content, which is in agreement with previous data.  
 
 
 
 
 
 
 
 
 
 
 
 
	  79	  
Introduction: Lipid profile of RAW264.7 cells  
 
 As previously discussed, RAW cells dynamically change their metabolism in 
response to different energy substrates, as well as LPS-stimulated activation. In addition 
to the study of energy metabolism, the lipid profiles of RAW cells in similar no glucose, 
glucose, and LPS culture conditions were also analyzed. However, the lipid analysis was 
performed after RAW cells were incubated in their respective culture conditions for 72 h 
in order to identify long-term lipid changes that may occur. Since RAW cells were 
incubated over a long time period, FBS was added to the media, and this contained 
glucose. Therefore, the lipid profile of a low glucose condition was studied and not a no 
glucose condition.  
The lipid of interest in this study was cardiolipin since this lipid is associated with 
energy metabolism. CL, an acidic phospholipid localized in the inner mitochondrial 
membrane, is integral in maintaining mitochondrial function and membrane integrity. 
Both CL content and fatty acid composition have been directly linked to the activities of 
the respiratory enzyme complexes, as discussed in Chapter 1. A high respiratory enzyme 
activity and oxygen consumption has been associated with high CL content, while a low 
respiratory enzyme activity and oxygen consumption has been associated with low CL 
content (22, 26, 27, 40, 47, 48). Therefore, it was hypothesized that, in RAW cells, the 
high oxygen consumption rate of cells grown in no glucose would be associated with 
high CL content, while the a low oxygen consumption rate of cells grown in glucose or 
treated with LPS would be associated with low CL content. A galactose condition was 
also included since previous studies have shown that the complete replacement of glucose 
by galactose significantly increases respiration in several different cell types (14, 21, 49, 
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50). Therefore, although not confirmed in this study, it was hypothesized that RAW cells 
grown in galactose media would display a high oxygen consumption rate or high 
respiration and would, therefore, have high CL content similar to cells grown in low 
glucose.  
Interestingly, another lipid of interest that presented itself in this study was 
phosphtidylserine (PS). PS is the most abundant negatively charged phospholipid in 
eukaryotic membranes and is found primarily in the inner leaflet of the plasma membrane 
(51) (Figure 22). The loss of this PS asymmetry in the membrane is associated with the 
recognition of apoptosis as well as blood coagulation (51). PS became a major lipid of 
interest after confirmation that three (or two) distinct lipid bands migrating at and near 
the PS standard were each confirmed to be PS (Figure 15, 17, 20). The variable migration 
of these three (or two) bands suggests that each band contains PS with fatty acyl chains of 
different lengths and degrees of saturation. However, the length and saturation of PS was 
not determined in this study. Only the content of PS and other lipids in RAW cells was 
analyzed.  
In this study, the lipid profiles of the following culture conditions were studied: 
glucose (10 mM), low glucose (0.05 mM), galactose (10 mM), and glucose (10 mM) + 
LPS (50 ng/mL), with particular focus on the CL content in each condition.  
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Materials and Methods 
 
Reagents 
HPLC grade methanol and chloroform were purchased from Sigma (St. Louis, 
MO, USA). DMEM, glucose, and glutamine were purchased from Sigma (St. Louis, 
MO, USA). Cell culture grade AlbuMAX I (lipid rich bovine serum albumin) was 
obtained from Gibco by Life Technologies (Grand island, NY, USA).  
 
Cell lines and culture conditions 
The murine macrophage RAW264.7 cell line was purchased from the American 
Type Culture Collection (Manassas, VA). The RAW cell line was maintained in 
Dulbecco’s Modified Eagle’s Medium (DMEM, Sigma, St. Louis, MO) with high 
glucose (25 mM) and supplemented with 10% fetal bovine serum (FBS, Sigma) and 50 
µg/mL penicillin-streptomycin (Sigma). The cells were maintained in a humidified 
incubator at 37ºC with 5% CO2. When the cells reached ~80% confluence they were 
counted using a TC20 and 30 million cells were seeded in five 150mm culture dishes for 
each condition. The RAW cells were allowed to seed for 3 h and were then washed 3x 
with dPBS. 15 mL of culture media for each of the four conditions was added. The four 
culture conditions are as follows:  
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After incubation for 72 h, the medium was removed from the RAW cells and the cells 
were scraped and washed 3x with dPBS. The cell pellet was then placed at -80° C for 1 h 
and lyophilized overnight for 16 h. The lyophilized cell pellets were weighed.  
 
Lipid isolation  
Total lipids were isolated and purified from 20mg lyophilized cell pellets. Lipid 
isolation was performed as described in Chapter 1.  
 
Column chromatography  
Performed as described in Chapter 2.  
 
 
1. Glucose (10mM) 2. Low Glucose 
(0.05mM) 
3. Galactose 
(10mM) 
4. Glucose (10mM) 
+LPS (50ng) 
DMEM (Sigma) DMEM (Sigma) DMEM (Sigma) DMEM (Sigma) 
10mM glucose   10mM glucose 
  10mM galactose   
2mM glutamine 2mM glutamine 2mM glutamine 2mM glutamine 
sodium bicarbonate 
(3.7 g/L) 
sodium bicarbonate 
(3.7 g/L) 
sodium bicarbonate 
(3.7 g/L) 
sodium bicarbonate 
(3.7 g/L) 
0.5 mg/mL 
Albumax 
0.5 mg/mL 
Albumax 
0.5 mg/mL 
Albumax 
0.5 mg/mL 
Albumax 
50 µg/mL 
penicillin-
streptomycin 
50 µg/mL 
penicillin-
streptomycin 
50 µg/mL 
penicillin-
streptomycin 
50 µg/mL 
penicillin-
streptomycin 
2% FBS (0.05 mM 
glucose) 
2% FBS 
(0.05mM glucose) 
2% FBS 
(0.05mM glucose) 
2% FBS 
(0.05mM glucose) 
   50 ng/mL LPS 
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Neutral lipid purification  
Following the separation of neutral and acidic lipids, the neutral lipids were dried 
in a Genevac EZ-2 evaporator (Genevac SP Scientific, Stone Ridge, NY). The dried 
neutral lipid fraction was suspended in 8 mL of CHCl3/CH3OH (1:1, v/v). The neutral 
lipid samples were then dried under a stream of nitrogen and suspended in 2 mL of 
CHCl3/CH3OH  (1:1 v/v).  
 
Acidic lipid purification  
Performed as described in Chapter 2.  
 
HPTLC 
 Neutral and acidic lipids were qualitatively analyzed using high-performance 
thin-layer chromatography (HPTLC) with modifications as previously described (34) 
(36). Neutral and acidic lipids were spotted on 10 x 10 cm Silica gel 60 HPTLC plates 
using the Camag Linomat V auto-TLC spotter (Camag Scientific Inc., Wilmington, NC, 
USA). The amount of neutral and acidic lipids spotted on the HPTLC was equivalent to 
70µg and 400µg of cell dry weight, respectively. An internal standard (oleyl alcohol) was 
added to the acidic lipid samples as a control for the amount of lipids spotted. Acidic and 
neutral lipid standards were purchased from Matreya (Pleasant Gap, PA). The neutral and 
acidic HPTLC plate was developed and visualized as described previously (36).  
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Identification of PS on HPTLC  
 PS was detected on HPTLC by ninhydrin reagent. The ninhydrin reagent was 
prepared by agitating 200mL of butanol with 200mL of dH2O in a 400mL separatory 
funnel. The lower aqueous phase was discarded and the upper phase collected. 0.2g of 
ninhydrin was dissolved in 100 mL of the butanol saturated with water and the reagent 
was put in a spray bottle. The HPTLC plate was developed as previously described. The 
plate was allowed to dry for 15 minutes and then sprayed with the 0.2% ninhydrin 
reagent. The HPTLC plate was then placed face-up and heated at 100°C for 2 minutes 
until red-violet spots appeared.  
 
Statistics  
Statistical analyses were performed on all data using IBM SPSS 21 Statistics 
Software. Two-tailed t-tests were performed and the significance values were determined 
where indicated. 	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Results  
 
Acidic lipids  
 RAW cells were incubated for 72 h in media containing glucose (10 mM), low 
glucose (0.05 mM), galactose (10 mM), and glucose (10 mM) + LPS (50 ng/mL). The 
acidic lipid profile from the RAW cells in these conditions showed that RAW cells in the 
low glucose condition had a significantly higher percent distribution of CL (21.3 ± 2.7 %) 
compared to the content of CL in the 10mM glucose sample (14.0 ± 0.9 %) (Figure 17; 
Table III). The percent composition of CL was also significantly higher in the galactose 
(20.6 ± 2.4 %) and glucose + LPS (18. 7 ± 0.6 %) condition compared to the glucose 
condition (14.0 ± 0.9 %) (Table III). There were no significant differences in CL percent 
distribution when comparing the galactose and LPS conditions to the low glucose 
condition (Table III).  
 Interestingly, PS contained three bands in the glucose and glucose + LPS samples, 
two bands in the galactose sample, and two bands with a faint third band low glucose 
sample (Figure 17, 19). The characterization of each of these bands as PS was confirmed 
using ninhydrin reagent (Figure 22). Ninhydrin reagent detects the free amino group on 
the PS lipid molecule (Figure 21).  
 Additionally, the differential migration of phosphatidic acid (PA) was also noted 
when comparing the acidic lipid profiles of each growth condition. PA appeared to 
migrate a greater distance from the origin in the low glucose and galactose conditions 
compared to the glucose and glucose + LPS conditions (Figures 17,19). Further analysis 
of the fatty acid composition of PA would need to be performed in order to better 
understand these differences in migration on HPTLC.  
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Neutral lipids  
The neutral lipid profile of RAW cells incubated for 72 hours in media containing 
glucose (10 mM), low glucose (0.05 mM), galactose (10 mM), and glucose (10 mM) + 
LPS (50 ng/mL) was also analyzed (Figures 18,20). The percent composition of 
phosphatidylcholine (PC) was significantly greater in the low glucose condition (35.7 ± 
0.6 %) in comparison to the glucose sample (33.0 ± 0.4 %) (Table IV). The PC content in 
the galactose sample was not significantly different from the glucose sample (Table IV). 
While, the percent composition of PC in the glucose + LPS sample was significantly 
lower (31.8 ± 0.3 %) than the PC content in the glucose sample (33.0 ± 0.4 %) (Table 
IV).  
The percent composition of phosphatidylethanolamine (PE) in both the low 
glucose and galactose conditions were significantly higher than the glucose and glucose + 
LPS conditions (Table IV). The percent composition of cholesterol (C) was significantly 
lower in both the low glucose and galactose conditions in comparison to the glucose and 
glucose + LPS conditions (Table IV).  
Interestingly, there was a trace amount of sphingomyelin (SPM) lipid in the lipid 
fraction isolated from the galactose grown cells (Table IV).  
 
RAW Cell Growth  
 The growth of RAW cells incubated for 72 h in media containing glucose (10 
mM), low glucose (0.05 mM), galactose (10 mM), and glucose (10 mM) + LPS (50 
ng/mL) was also analyzed (Figure 23). Growth was assessed by cell dry weight. The low 
glucose, galactose, and glucose + LPS condition dry weights were significantly lower 
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than the glucose dry weight after 72 h (Figure 23). The galactose and no glucose 
condition cell dry weights were significantly lower than the glucose + LPS cell dry 
weight after 72 h (Figure 23). Additionally, the no glucose cell dry weight was 
significantly lower compared to the galactose dry weight (Figure 23).  
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Discussion  
 
Cardiolipin content   
RAW cells display a robust Crabtree effect in vitro. RAW cells incubated in 
glucose media had a significantly lower oxygen consumption rate (OCR) and 
significantly higher extracellular acidification rate (ECAR) compared to RAW cells 
incubated in no glucose media (Figure 1 and 2). However, these metabolic measurements 
were obtained over a short, two hour time period. In order to study possibly more 
dramatic changes in the lipid composition of RAW cells that may occur over a longer 
time period, RAW cell lipid analysis was performed after a 72 h incubation period. Since 
cells were incubated for 72 h, fetal bovine serum (FBS) was added to the media to 
support cell viability. Since 2% FBS, which contained glucose, was added to the media, a 
low glucose condition was studied instead of a strictly no glucose condition.  
 The lipid of interest in this study was CL since its content has been associated 
with the level of cellular respiration. It was previously shown that RAW cells incubated 
in no glucose media have a higher respiration than RAW cells incubated in glucose 
media. Therefore, it was expected that RAW cells incubated in low glucose media would 
have a significantly higher CL content than RAW cells incubated in glucose media. 
These expectations were confirmed in this study. The data, therefore, correlate with 
previous data showing a direct relationship between CL content and respiration level (22, 
26, 27, 40, 47, 48). 
 RAW cells were also incubated in media containing galactose for 72 h to study 
the replacement of glucose with an energy substrate found to increase respiration. 
Previous studied showed that several different cell types (fibroblasts, cancer cells, and 
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myotubes (developing skeletal muscle fiber)) grown in galactose media show 
significantly increased oxygen consumption rates and a decreased glycolytic rate 
compared to cells cultured in high glucose medium (14, 21, 49, 50). RAW cells incubated 
in galactose media for 72 h displayed a significantly higher CL content compared to 
RAW cells incubated in glucose. In order to determine if this increase in CL content is 
concomitant with an increase in respiration, an assay determining OCR and ECAR 
measurements of RAW cells in galactose media must be performed.  
 RAW cells activated with 50 ng/mL LPS also showed higher CL content 
compared to non-activated RAW cells. LPS-activation was previously shown to decrease 
RAW cell respiration, therefore, it was expected that LPS-activation would decrease CL 
content. However, the long, 72-hour duration of RAW cell incubation in 50 ng/mL LPS 
may have diminished the effect of LPS on cellular respiration and CL content.  
 
Phosphatidylserine (PS) and phosphatidylethanolamine (PE) content   
 A major lipid of interest that presented itself in this study was PS, which 
displayed a variable migration pattern in response to different energy substrates or LPS-
activation. RAW cells incubated in 10 mM glucose media and RAW cells activated with 
LPS showed three distinct PS lipid bands, while RAW cells incubated in low glucose and 
galactose media showed two distinct PS lipid bands. It has been previously found in the 
yeast Saccharomyces cerevisiae that the level of CHO1 mRNA, encoding the PS 
synthase enzyme, decreases when cells transition from fermentation in glucose media to 
respiration in glycerol media (52). CHO1 mRNA levels have also been shown to increase 
in response to oxygen deprivation (53). Therefore, a decrease in mitochondrial respiration 
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results in an increase in CHO1 transcript levels and, presumably, an increase in the 
number of PS molecules. In agreement with these data, RAW cells incubated in 
fermentative cell culture conditions, such as glucose, displayed higher PS content 
compared to RAW cells incubated in respiratory cell culture conditions, such as low 
glucose and galactose.  
However, the synthesis of PS is different in prokaryotes and the yeast 
Saccharomyces cerevisiae compared to mammalian cells. In Saccharomyces cerevisiae, 
all PS is synthesized by a PS synthase that uses CDP-diacylglycerol and L-serine as 
substrates. While, in mammalian cells PS is synthesized by calcium-dependent base-
exchange reactions in which the polar head-group (choline or ethanolamine) of a pre-
existing phospholipid (PC or PE, respectively) is exchanged for L-serine (54). 
Furthermore, prokaryotes and S. cerevisiae contain a single PS synthase, while 
mammalian cells express two PS synthase enzymes (PSS1 and PSS2) that are encoded by 
two different genes (54). Therefore, the transcriptional response of PSS1 and PSS2 to the 
metabolism of different energy substrates by mammalian cells must be studied to be able 
to determine if mammalian cells also increase transcription of their PS synthases in 
response to a decrease in mitochondrial respiration.  
Additionally, further analysis of the PS fatty acid composition must be performed 
since each condition studied showed variable migration of PS on HPTLC. The fatty acid 
chain composition may be an important consideration in the synthesis of PE though the 
decarboxylation of PS in the mitochondria by PS decarboxylase (PSD). Mitochondrial PE 
deficiency has been shown to result in the alteration of mitochondrial morphology, 
decreased ATP production, decreased oxygen consumption, and altered activity of the 
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electron transport chain enzymes (55, 56). Therefore, similar to CL, the fatty acid 
composition of PE, inherited from PS through its decarboxylation, may also affect 
mitochondrial function. Furthermore, in agreement with the above PE data, a decrease in 
PE content was seen in RAW cells incubated in glycolytic conditions (glucose and LPS-
activation), while a significantly higher PE content was seen in RAW cells incubated in 
respiratory conditions (low glucose and galactose).  
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Figure 17. HPTLC of acidic lipids in RAW cells incubated for 72 h in glucose (10 
mM) and low glucose (0.05 mM) media. Five individual glucose (10 mM) and low 
glucose (0.05 mM) RAW cell populations were analyzed. The abbreviations used are as 
follows: O, origin; PS, phosphatidylserine; PI, phosphatidylinositol; Sulf, sulfatides 
(doublet); PA, phosphatidic acid; CL, cardiolipin; IS, internal standard (oleyl alcohol); 
FFA, free fatty acid; and SF, solvent front of the first developing solvent system.  
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Figure 18. HPTLC of neutral lipids in RAW cells incubated for 72 h in glucose (10 
mM) and low glucose (0.05 mM) media. Five individual glucose (10 mM) and low 
glucose (0.05 mM) RAW cell populations were analyzed. The abbreviations used are as 
follows: O, origin; SPM, sphingomyelin; PC, phosphatidylcholine; PE, 
phosphatidylethanolamine; CB, cerebrosides (doublet); CM, ceramide; C, cholesterol; IS, 
internal standard (oleyl alcohol); TG, triglycerides; CE, cholesterol ester; and SF, solvent 
front of the first developing solvent system. 
	  95	  
  
	  96	  
 
Figure 19. HPTLC of acidic lipids in RAW cells incubated for 72 h in galactose (10 
mM) and glucose (10 mM) + LPS (50 ng/ mL) media. Five individual galactose (10 
mM) and glucose (10 mM) + LPS (50 ng/mL) RAW cell populations were analyzed. The 
abbreviations used are as follows: O, origin; PS, phosphatidylserine; PI, 
phosphatidylinositol; Sulf, sulfatides (doublet); PA, phosphatidic acid; CL, cardiolipin; 
IS, internal standard (oleyl alcohol); FFA, free fatty acid; and SF, solvent front of the first 
developing solvent system.  
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Figure 20. HPTLC of neutral lipids in RAW cells incubated for 72 h in galactose (10 
mM) and glucose (10 mM) + LPS (50 ng/mL) media. Five individual galactose (10 
mM) and glucose (10 mM) + LPS (50 ng/mL) RAW cell populations were analyzed. The 
abbreviations used are as follows: O, origin; SPM, sphingomyelin; PC, 
phosphatidylcholine; PE, phosphatidylethanolamine; CB, cerebrosides (doublet); CM, 
ceramide; C, cholesterol; IS, internal standard (oleyl alcohol); TG, triglycerides; CE, 
cholesterol ester; and SF, solvent front of the first developing solvent system. 
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Table IV. Percent Distribution of Neutral Lipids in RAW264.6 Cells 
   ! ! ! ! ! !
Neutral Lipids b 
RAW264.7 Cells 
Glucose 
(10mM)a Low Glucose (0.05mM)a Galactose (10mM)a Glucose (10mM) + LPS (50ng)a 
Sphingomelin (SPM) 
   
  
  
Trace  
  
  
 
  
Phosphatidylcholine (PC) 33 ± 0.4 35.7 ± 0.6 * 32.7 ± 0.8 31.8 ± 0.3 * 
Phosphatidylethanolamine (PE) 24.6 ± 1.3 28.4 ± 2 * 28.6 ± 1.7 * 23.9 ± 1.4 
Cholesterol (C)  42.5 ± 1.1 35.9 ± 1.4 * 39.5 ± 1.4 * 43.6 ± 0.9 
! ! ! ! ! ! ! ! ! ! ! ! !a Values are expressed as the mean percent distribution ± SD (n = 5 independent samples) 
  ! ! ! ! ! !b Determined from densitometric scanning of HPTLC as shown in Fig. 16 and 18 
! !    * Indicates significance of the indicated culture condition from the Glucose (10mM) culture condition in RAW  
!    cells at p < 0.05 as determined by independent-samples T Test 
    ! ! ! ! ! !
       ! ! ! ! ! !!
Table III. Percent Distribution of Acidic Lipids in RAW264.6 Cells 
   ! ! ! ! ! !
Acidic Lipids b 
RAW264.7 Cells 
Glucose (10mM)a Low Glucose (0.05mM)a Galactose (10mM)a Glucose (10mM) + LPS (50ng)a 
Phosphatidylinositol (PI) 27.1 ± 1.3 21.7 ± 1.8 * 19.7 ± 0.6 * 23.4 ± 0.9 * 
Phosphatidylserine (PS) 36.6 (3) ± 1.9 31.8 (2*) ± 2.2 * 25.0 (2) ± 2.3 * 30.7 (3) ± 1.2 * 
Phosphatidic Acid (PA) 22.4 ± 1.6 25.1 ± 1.4 34.3 ± 0.6 * 27.3 ± 1.5 * 
Cardiolipin (CL) 14.0 ± 0.9 21.3 ± 2.7 * 20.6 ± 2.4 * 18.7 ± 0.6 * 
       ! ! ! ! ! !a Values are expressed as the mean percent distribution ± SD (n = 5 independent samples) 
  ! ! ! ! ! !b Determined from densitometric scanning of HPTLC as shown in Fig. 15 and 17 
! ! ! ! !* Indicates significance of the indicated culture condition from the Glucose (10mM) culture condition in RAW  
! ! ! !cells at p < 0.05 as determined by independent-samples T Test 
    ! ! ! ! ! !(2/3) indicates the number of PS lipid bands; (2*) indicates a faint 3rd band in this condition   
  ! ! ! ! ! !
 ! ! ! ! ! ! ! ! ! ! ! !!
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Figure 21. Structure of phosphatidylserine. Phosphatidylserine (PS) is a 
phosphoglyceride containing a phosphorylserine head group. PS(10:0/10:0) is one of 
many PS molecular species. Adapted from LIPID MAPS Lipidomics Gateway.  
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Figure 22. Identification of PS. HPTLC plates were spotted and developed as discussed 
in the Materials and Methods. The HPTLC plate was then sprayed with a 0.02% 
ninhydrin in butanol solution and heated. The detection of PS was confirmed using a PS 
standard.   
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Figure 23. RAW cell growth in glucose (10 mM), low glucose (0.05 mM), galactose 
(10 mM), and glucose (10mM) + LPS (50 ng/mL) media for 72 h. Cell growth was 
analyzed by cell dry weight using the average dry weight of 30 million cells (five 
replicates) * indicates significance of p < 0.05 compared to the glucose (10 mM) 
condition. § indicates significance of p < 0.05 compared to the glucose (10 mM) + LPS 
(50 ng/mL) condition. ψ indicates significance of p < 0.05 of the low glucose (0.05 mM) 
condition compared to the galactose (10 mM) condition.   
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CHAPTER 5 
 
CONSIDERATIONS FOR IN VIVO STUDIES USING THE VM-M3 
METASTATIC CANCER MODEL 
 
Connection to Chapter 2: As discussed in Chapter 2, the Crabtree effect and CL profile 
of the VM-M3 cells were studied in vitro. An in vivo extension of this study would utilize 
the VM-M3 mouse model of metastatic cancer. However, a better understanding of the 
variable tumor growth and/or metastasis within the VM-M3 mouse model needs to be 
established before such studies are performed. 
 
Background: The VM-M3 mouse model is a powerful synergistic model of metastatic 
cancer. The subcutaneous injection of the VM-M3 cell line into the flank of the VM/Dk 
synergistic host results in primary tumor formation and systemic metastasis to multiple 
organ systems (liver, lung, spleen, kidney, and brain). The VM-M3 cells are transduced 
with a lentiviral vector expressing luciferase (VM-M3/Fluc) so the progression of 
primary tumor growth and systemic metastasis can be monitored by bioluminescence 
imaging (BLI). However, when the same number of VM-M3 cells is inoculated 
subcutaneously into the flanks of a cohort of age and sex matched VM mice, the whole 
body photon flux of each animal on a specified day can be exceedingly different.  
 
Methodology and Principle Observations: The aim of this study was to determine if a 
cohort of age and sex matched VM mice inoculated with VM-M3 cells could be divided 
into “high whole body bioluminescence” or “fast progression” and “low whole body 
bioluminescence” or “slow progression” groups using whole body bioluminescence, and 
whether the mice within each group would display similar metastasis bioluminescence 
and primary tumor weight at the termination of the study. Overall, the aim of this study 
was not supported by the data collected in this experiment.  
 
Conclusions and Significance: The proposed screen was not predictive of both ex vivo 
metastasis and primary tumor wet weight at the termination of the study. Therefore, a 
new method of understanding the variation in VM-M3 tumor progression, invasion, and 
metastasis must be established. Understanding such variation in VM-M3 tumor 
progression is essential for determining if a particular treatment shows efficacy in the 
VM-M3 model or if some of the treated mice inherently have slower growing primary 
tumors and/or a slower metastatic progression. 
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Introduction: In vivo VM-M3 metastatic cancer model screen  
 
As discussed in Chapter 2, the Crabtree effect and CL profile of the VM-M3 cells 
were studied in vitro. An in vivo extension of this study would utilize the VM-M3 mouse 
model of metastatic cancer. However, a better understanding of the variable tumor 
growth and/or metastasis within the VM-M3 mouse model needs to be established before 
such studies are performed. Therefore, the final chapter of this thesis discusses a 
screening technique for the VM-M3 mouse model as a possible means of better 
organizing experimental groups for studies using this in vivo cancer model.  
 
Mouse preclinical models of cancer   
Mouse models of cancer are invaluable tools for studying the molecular basis of 
cancer and the development of new cancer therapies. However, many mouse models of 
cancer, including human tumor xenograft models and genetically engineered mouse 
models (GEMMs), are limited to modeling the initiation and progression of primary 
tumor growth (57). Systemic metastasis, or the spread of tumor cells to multiple organ 
systems, is responsible for the majority of cancer deaths. The VM-M3 metastatic cancer 
mouse model is such a model in which implanted cells invade locally from the implanted 
tissue site and spread to multiple organ systems within 2-4 weeks time. The VM-M3 
model represents a more natural model of metastatic cancer and displays many of the 
growth characteristics of human metastatic cancers.   
The VM/Dk (VM) mouse strain has a high incidence of spontaneous brain tumor 
formation (1.5%) with most brain tumors being classified as gliomas (33). The VM-M3 
mouse model was generated from the spontaneous brain tumor of a VM mouse detected 
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during the routine examination of the colony between 1993-2000. The tumor-bearing 
mouse presented cranial swelling and lethargy. The tumor was passaged both 
intracerebrally (i.c.) and subcutaneously (s.c) before a cell line was established from the 
tumor and classified as “VM-M3.” The subcutaneous injection of the VM-M3 cell line 
into the flank of the VM/Dk synergistic host results in primary tumor formation and 
systemic metastasis to multiple organ systems (liver, lung, spleen, kidney, and brain). 
Furthermore, since the VM-M3 cells are transduced with a lentiviral vector expressing 
luciferase (VM-M3/Fluc), the progression of primary tumor growth and systemic 
metastasis is able to the monitored in the VM-M3 model by bioluminescence imaging 
(BLI) using luciferin. The VM-M3 mouse model is a powerful synergistic model of 
metastatic cancer.  
 
Mouse cancer model variability  
In addition to the type of cancer model used in preclinical studies, the variability 
of tumor take and tumor growth within the model must also be considered. Several 
models of cancer have wide ranges of tumor cell take rate, growth, and metastatic 
capacity (58–60). Therefore, studies often stratify the mice into treatment groups to 
obtain similar average tumor sizes in each group or restrict the mice enrolled in the study 
to those that have a specific primary tumor size range (60). In such studies, the mice are 
screened prior to the initiation of the experiment. This screening procedure may remove 
mice from the study to develop homogenous treatment populations. However, the 
addition of these mice to the study may better model human cancers, as human cancer 
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cohorts are heterogeneous. However, including mice of variable tumor size may interfere 
in determining if a treatment shows statistical significance in a preclinical model.  
 
VM-M3 model variability  
 Since the progression of primary tumor growth and systemic metastasis is able to 
the monitored in the VM-M3 model by bioluminescence imaging (BLI), the growth of 
the VM-M3 tumors can be assessed before palpable tumors are detected and metastatic 
spread can be monitored. Bioluminescence of the VM-M3 mice may be obtained on any 
day following the inoculation of VM-M3 cells. However, it has been observed that when 
the same number of VM-M3 cells is inoculated subcutaneously into the flanks of a cohort 
of age and sex matched VM mice, the whole body photon flux of each animal on a 
specified day can be exceedingly different. Some animals display high bioluminescence 
while other animals display very little bioluminescence on, for example, day 6 post 
inoculation. This indicates that there is differential tumor take, growth, and/or metastasis 
within the VM-M3 model. Therefore, it becomes difficult to assess whether a treatment 
has efficacy or the particular mouse being treated has an underlying propensity to 
develop VM-M3 tumors and metastasis at a slower rate.  
 Therefore, the aim of this study was to determine if a cohort of age and sex 
matched VM mice inoculated with VM-M3 cells could be divided into “high whole body 
bioluminescence” or “fast progression” and “low whole body bioluminescence” or “slow 
progression” groups using whole body bioluminescence. And, whether the mice within 
each group would display similar metastasis bioluminescence and primary tumor weight 
at the termination of the study.    
	  111	  
Materials and Methods  
 
Mice  
 
 Mice of the VM/Dk strain were originally obtained from H. Fraser (University of 
Edinburgh) and from G. Carlson (McLaughlin Research Institute, Great Falls, Montana). 
The mice were housed and bred in the Boston College Animal Care Facility. The mice 
were group housed (4 mice/ cage) in plastic cages with filter tops containing Sani-Chip 
bedding (P.J. Murphy Forest Products Corp., Montville, NJ, USA). The room was 
maintained at 22°C on a 12-h light/dark cycle. Food (PROLAB R/M/H/3000 Laboratory 
Chow, Agway, St Louis, MO, USA) and water were provided ad libitum. All animal 
procedures were in strict accordance with the NIH Guide for the Care and Use of 
Laboratory Animals and were approved by the Institutional Animal Care and Use 
Committee (IACUC).  
 
VM-M3 cell line 
The VM-M3 cell line was previously established from the flank-grown 
spontaneous VM-M3 tumor isolated from the cerebellum of a VM/Dk strain mouse (33).  
The cells were maintained in Dulbecco’s Modified Eagle’s Medium (DMEM, Sigma, St. 
Louis, MO) with high glucose (25 mM) and supplemented with 10% FBS (Sigma) and 50 
µg/mL penicillin-streptomycin (Sigma), and phenol red (Sigma) (DMEM Complete 
media). The cells were maintained in a humidified incubator at 37ºC with 5% CO2. 24 h 
prior to inoculation into the VM Mice, the VM-M3 cells were serum starved.  
 
 
 
 
	  112	  
Tumor cell inoculation   
 
 VM-M3 cells were re-suspended in dPBS at a density of 4 x 106 cells/mL. Mice 
were anesthetized with isoflourane and injected subcutaneously with 2 x 106 cells in 
dPBS (500 µL) using a 28-gauge insulin syringe.  
 
In vivo bioluminescence imaging  
 
Mice were imaged with the Xenogen IVIS system (Xenogen, Hopkington, MA) to 
quantify the bioluminescence signal from the VM-M3/Fluc tumors. The IVIS Lumina 
cooled CCD camera system was used for light acquisition. The Xenogen system is 
coupled to a PC with LivingImageTM software for data acquisition and analysis 
(Xenogen). For in vivo imaging, mice received an i.p. injection of d-luciferin (50 or 150 
mg/kg, Promega). Eight minutes after the luciferin injection, mice were anesthetized in a 
clear plastic chamber filled with a 2% isoflourane/air mixture. Isoflourane anesthesia was 
maintained using a nose cone delivery system during image acquisition. Two mice were 
imaged together using black plastic dividers to prevent the penetration of light photons 
from one mouse to another. A grey scale body image was first collected followed by the 
acquisition of the pseudocolor image showing the distribution of photon counts emerging 
from the luciferase vectors within the mouse. The photon flux is proportional to the 
number of luciferase expressing VM-M3 cells in the mouse. The grey scale and 
pseudocolor image are overlaid in each picture analyzed.  An integration time of 1 min 
was used for bioluminescent image acquisition. Mice were imaged on both the dorsal side 
(back) and lateral left side. Signal intensity was quantified as the sum of all detected 
photon counts within a region of interest (ROI) covering the whole mouse body or 
specific regions using the LivingImage software.  
	  113	  
Ex vivo bioluminescence imaging  
 
 After sacrifice by CO2, the liver, lung, brain, kidneys, and spleen were harvested 
from each mouse. The tissues were rinsed in PBS and then placed in a 50mL conical with 
10mL of D-Luciferin (300 µg/mL) in dPBS for 10 minutes. Each tissue was then 
arranged on four petri dishes and imaged using the Xenogen IVIS system. An integration 
time of 1 min was used for bioluminescent image acquisition. 
 
Animal survival  
 The health and behavior of the mice was assessed daily. Mice were humanely 
euthanized by CO2 according to approved IACUC guidelines upon presentation of the 
defined criteria associated with tumor burden and disease progression. Such behaviors 
include abnormal feeding, diminished response to stimuli and failure to thrive.   
 
 
Primary tumor wet weight  
 
Primary tumors were harvested from each mouse after sacrifice by CO2 and flash-
frozen in liquid nitrogen. The wet weight of each tumor was then determined.  
 
Statistics  
Statistical analyses were performed on all data using IBM SPSS 21 Statistics 
Software. Two-tailed t-tests were performed and the significance values were determined 
where indicated. Survival was analyzed by Kaplan-Meier.  
 
 
 
	  114	  
Results 
 
Variable tumor growth/ metastasis in the VM-M3 mouse model  
 VM mice inoculated with the VM-M3 cell lines display variable rates of disease 
progression. When inoculated with 2 x 106 VM-M3 cells, some mice display high whole 
body bioluminescence during imaging time points throughout VM-M3 tumor 
progression, while others display low bioluminescence. In a representative image of this 
phenomenon, mouse 1 displayed similar bioluminescence as mouse 2 on days 9 and 18 
post inoculation. However, on day 28, mouse 1 displayed a greater bioluminescence 
compared to mouse 2 (Figure 24A). Mouse 1 and 2 were both males of the same age. 
This suggests that the growth and invasion of the VM-M3 cells throughout the body of 
mouse 1 is much greater than that of mouse 2 at 29 days post inoculation. Although both 
mouse 1 and mouse 2 appear to have a similar rate of disease progression on days 9 and 
18, the disease progression of mouse 1 accelerates much faster than mouse 2 18-28 days 
post inoculation.  
 The rate of disease progression in the VM-M3 metastatic cancer model can also 
be analyzed by survival. The survival of 11 female VM mice of similar age (5 months) 
inoculated with 2 x 106 VM-M3 cells is depicted in Figure 24 B and C. The mean 
survival was 35 ± 6 days (Figure 24B,C). The high standard deviation indicates that the 
survival rates have a wide spread. In fact, the range of the survival data was 22 days. 
These data suggest that the rate of disease progression in VM-M3 metastatic model, when 
assessed by survival, is variable among a cohort of animals of a similar age and sex.  
 In light of these data, it was hypothesized that a cohort of sex and age matched 
VM-M3 mice could be divided into two individual groups (screened) based upon a 
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“slow” and “fast” progression of disease. Once divided, the groups may be analyzed at 
the conclusion of the study for metastatic progression and primary tumor weight in order 
to assess if such a screen is predictive of similar metastatic spread and/or tumor size 
within the “slow progression” or “fast progression” groups.  
 
D-Luciferin dose for bioluminescence imaging  
 Before bioluminescence studies are performed, the dose of luciferin used must be 
considered in terms of finding a dose that saturates most luciferase vectors and can be 
tolerated during repeated bioluminescence imaging. Most companies that produced d-
luciferin recommend a dose of 150 mg/kg in mice (Perkin Elmer, Caliper, Promega, Gold 
Biotechnology). However, as seen in Figure 27, a higher 300 mg/kg dose of luciferin 
results in an overall higher photon flux compared to 150 and 50 mg/kg. Therefore, in the 
particular mouse model tested by Xenogen, 150 mg/kg is not a saturating dose of 
luciferin. However, the high cost of d-luciferin must also be taken into account when 
determining luciferin dose. Therefore, even though 150 or 50 mg/kg may not saturate all 
luciferase vectors, these doses are chosen in the interest of cost. Comparisons of control 
and experimental groups within a study are based upon administration of the same dose 
of luciferin to each mouse.  
Furthermore, the transfection of tumor cells with a luciferase vector allows for the 
monitoring of tumor growth over time through repeated bioluminescence imaging of 
tumor-bearing mice. Therefore, the tolerance of luciferin is also an important 
consideration when determining the best luciferin dose. Dosages of 300mg/kg and up to 
750mg/kg have been shown to be well tolerated in mice (61). Such high dosages were 
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necessary when studying tumors implanted in the brain due to the tissue light absorbance 
from hemoglobin and melanin as well as the reduction in diffusion of luciferin through 
the blood brain barrier (61).  
In this study, a comparison of the 50mg/kg luciferin dose, previously used in VM-
M3 studies, and the standard 150mg/kg luciferin dose was performed. However, prior to 
bioluminescence imaging of mice at these luciferin doses, the kinetics of each dose in the 
tumor bearing VM-M3 model was determined since a new anesthesia method was 
performed in the study.  
 
Luciferin kinetic curve  
 Previously, in vivo bioluminescence imaging of the VM-M3 mice was performed 
using avertin as the anesthetic. Avertin was administered at the same time as d-luciferin. 
However, since avertin anesthesia is unable to be controlled when the mice are in the 
Xenogen machine, a kinetic curve of d-luciferin in the VM-M3 model was not obtained. 
It is important to obtain a kinetic curve of d-luciferin in a specific mouse model because 
even though the biodistribution of luciferin is rapid, the kinetics of the luciferase reaction 
with luciferin are tissue dependent (62). Therefore, since the Xenogen system is equipped 
with nose cones for isoflourane administration during imaging, a kinetic curve of d-
luciferin at both 50 and 150 mg/kg was obtained in the VM-M3 model using two mice for 
each dose. The kinetic curves of luciferin in the VM-M3 mice were generated 3 days post 
inoculation. It was found that a maximum photon flux was detected 20.75 min after the 
i.p. administration of 150 mg/kg d-luciferin (Figure 25A). Furthermore, the photon flux 
13-18 min post d-lucirferin administration displayed a gradual increase (Figure 25B). The 
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photon flux 22.5-26.5 min after luciferin injection was relatively constant (Figure 25C). 
Therefore, a bioluminescence imaging protocol was established in which all 
bioluminescence measurements were obtained 18-23 min after luciferin injection. For all 
bioluminescence imaging using 150 mg/kg d-luciferin, the dorsal side was imaged 18:00 
min post luciferin administration, the lateral left side imaged at 19:30, the ventral side 
imaged at 21:00, and the lateral right side imaged at 22:30 min. A 1.5-min delay between 
image acquisitions was established in order to allow time to change position and grey 
scale image the mouse.  
 For the 50 mg/kg dose of luciferin, the maximal photon flux occurred around 10 
min and rapidly decreased thereafter (data not shown). Therefore, for all bioluminescence 
imaging using a 50 mg/kg dose of d-luciferin, the dorsal side was imaged 9:00 min post 
luciferin administration, the lateral left side imaged at 10:30, the ventral side imaged at 
12:00, and the lateral right side imaged at 13:30 min. 
The time of the maximal photon flux detected in the VM-M3 mouse model 
following i.p. injection of both 50 and 150 mg/kg d-luciferin is similar to that detected by 
the Xenogen Corporation in the mouse model utilized for kinetic analysis of luciferin at 
different concentrations (63).  
 
VM-M3 Screen: bioluminescence 5 and 8 days Post inoculation  
 After determining the kinetics of luciferin in the VM-M3 model, the screen was 
initiated. 26 VM mice were inoculated with 2 x 106 cells subcutaneously in the left flank. 
The whole body bioluminescence of 16 mice was obtained using the recommended 150 
mg/kg luciferin dose on days 5 and 8 post inoculation (Figure 26 and 27). The whole 
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body bioluminescence of 10 mice was obtained using the 50mg/kg dose on days 5 and 8 
post inoculation (Figure 26 and 27). Overall, the mice imaged using 150mg/kg luciferin 
displayed a higher photon flux than mice injected with 50mg/kg luciferin (Figure 26 and 
27). Therefore, the higher 150mg/kg dose of luciferin saturates more luciferase vectors 
and gives a more sensitive quantification of VM-M3 cells in the VM mouse.  
 A comparison of the day 5 and day 8 data also displays variation in the growth 
and/or invasion of VM-M3 cells. For example, mouse 2.4 on day 5 displayed moderate 
whole body bioluminescence in comparison to the other mice imaged using the 150mg/kg 
luciferin dose (Figure 26). However, on day 8, mouse 2.4 had the highest whole body 
bioluminescence of all mice imaged using the 150 mg/kg luciferin dose (Figure 27). 
Overall, mouse 2.4 showed a large increase in whole body bioluminescence between days 
5 and 8 post inoculation. Mouse 3.4 on day 5 displayed the second highest whole body 
bioluminescence of all mice imaged using the 150 mg/kg luciferin dose (Figure 26). And, 
on day 8, this mouse displayed the sixth highest whole body bioluminescence of all mice 
imaged using the 150 mg/kg luciferin dose (Figure 27). Overall, mouse 3.4 showed a 
small increase in bioluminescence between days 5 and 8 post inoculation. Therefore, the 
large increase in bioluminescence of mouse 2.4 suggested that VM-M3 cells injected into 
this particular mouse showed accelerated growth and/or invasion compared to mouse 3.4.  
 
VM-M3 screen: bioluminescence 13 days post inoculation  
 The bioluminescence of all 26 VM mice bearing VM-M3 tumors was obtained 
using 150mg/kg luciferin 13 days post inoculation (Figure 28A). The mice were divided 
into “low whole body bioluminescence” and “high whole body bioluminescence” groups 
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(Figure 28B). The “high whole body bioluminescence” group had an average 
bioluminescence of 143 x 106 photons/ second, while the “low whole body 
bioluminescence” group had an average bioluminescence of 73 x 106 photons/ second 
(Figure 28B).  
Nine mice were chosen to continue in the screen study with three mice in the 
“low” and six mice in the “high” whole body bioluminescence groups (Figure 29A). It 
was determined that the mice were screened according to primary tumor size. A 
comparison between “primary tumor bioluminescence” and “metastasis 
bioluminescence” revealed that the majority of whole body bioluminescence was being 
generated by the primary tumor (Figure 30A). The primary tumors of each mouse in the 
screen were defined using the LivingImage software ROI tools (Figure 34). “Metastasis 
bioluminescence” was defined as the primary tumor bioluminesce subtracted from the 
whole body bioluminescence (Figure 34).  
 
End of study: primary tumor wet weight  
 Mice were sacrificed by CO2 29 days after inoculation. The primary tumor wet 
weight was obtained. The average primary tumor wet weight, although lower in the low 
whole body bioluminescence group, was not significantly different from the high whole 
body bioluminescence group (Figure 30A and B). The high whole body bioluminescence 
group had large variation as shown by the high standard deviation of the data (Figure 
31B). However, the high whole body bioluminescence group did have a higher 
percentage (66.6%) of tumor wet weights over 0.3 grams (Figure 30C). Therefore, even 
though the primary tumor wet weights were not significantly different between groups, a 
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higher proportion of tumors were larger in the high whole body bioluminescence group 
compared to the low whole body bioluminescence group.  
 
End of study: metastasis  
 The ex vivo bioluminescence of the kidney, lung, liver, spleen, and brain were 
also obtained (Figure 31). The bioluminescence of both sides of each organ was summed 
to determine the metastatic load of each mouse at the conclusion of the study (Figure 
31B). The ex vivo metastasis bioluminescence, although lower in the low whole body 
bioluminescence group, was not statistically different from the high whole body 
bioluminescence group (Figure 31C). The high whole body bioluminescence group had a 
large standard deviation showing a large variation in metastasis within this group (Figure 
31C). However, the high whole body bioluminescence group did have a higher 
percentage (80%) of metastasis bioluminescence above 2 x 107 photons/second (Figure 
31D). Therefore, even though the metastasis bioluminescence was not significantly 
different between groups, a larger number of mice in the high whole body 
bioluminescence group had greater metastasis compared to the low whole body 
bioluminescence group.  
 
 
Correlation between day 13 primary tumor bioluminescence and primary tumor 
wet weight 
 
 There was a strong positive linear correlation between the day 13 primary tumor 
bioluminescence and the day 29 primary tumor wet weight in the low whole body 
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bioluminescence group (r2 = 0.9546) (Figure 32). No correlation was shown in the high 
whole body bioluminescence group (Figure 32).  
 
Correlation between day 13 whole body bioluminescence and day 29 metastasis 
 
 There was a strong correlation between the whole body bioluminescence on day 
13 and the end of study (day 29) metastasis bioluminescence in the low whole body 
luminescence group (r2 = 0.9892) (Figure 33). However, this was a negative correlation, 
indicating that a lower whole body bioluminescence on day 13 was correlated with a high 
metastasis bioluminescence on day 29. No correlation between day 13 whole body 
bioluminescence and end of study (day 29) metastasis bioluminescence was shown in the 
high whole body bioluminescence group (Figure 33).  
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Discussion  
  
The goal of this study was to determine if a cohort of age and sex matched VM 
mice inoculated with VM-M3 cells could be divided into “high whole body 
bioluminescence” or “fast progression” and “low whole body bioluminescence” or “slow 
progression” groups using whole body bioluminescence analysis. The whole body 
bioluminescence of each mouse was analyzed 3, 5, and 13 days post inoculation. On days 
3 and 5, whole body bioluminescence showed that a 150mg/kg luciferin dose, overall, 
saturated more luciferase vectors than the 50mg/kg dose. The 150mg/kg dose provided a 
more accurate overview of VM-M3 tumor growth and/or invasion/metastasis within the 
VM mouse. The organization of mice into high whole body bioluminescence and low 
whole body bioluminescence groups was performed following analysis of day 13 post 
inoculation whole body bioluminescence data.  
 Nine mice were selected to continue in the screen study with 3 mice in the low 
whole body bioluminescence group and 6 mice in the high whole body bioluminescence 
group. At the conclusion of the study, it was found that there was not a statistically 
significant difference in both metastasis luminescence and primary tumor wet weight 
between the high and low bioluminescence groups. The high primary tumor 
bioluminescence group had highly variable tumor wet weights and metastasis 
luminescence. Therefore, screening mice into low and high bioluminescence on day 13 
post inoculation was not predictive of low and high metastasis bioluminescence or low 
and high primary tumor wet weight at the end of the study. Since it was determined that 
the majority of bioluminescent signal was emerging from the primary tumor at day 13, a 
comparison between the day 13 primary tumor bioluminescence and day 29 (end of 
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study) tumor wet weight was performed using a linear regression model. It was found 
that a positive linear correlation between day 13 primary tumor bioluminescence and day 
29 primary tumor wet weight existed only in the low whole body bioluminescence group. 
Therefore, if studying primary tumor growth, including only animals with low 
bioluminescence may reduce variation. However, the focus of the VM-M3 preclinical 
mouse model is metastasis, since metastasis is the primary cause of death in cancer 
patients. A linear correlation did not exist between day 13 whole body bioluminescence 
and metastasis bioluminescence in the high whole body luminescence group. While, 
interestingly, a negative linear correlation was demonstrated by the low whole body 
luminescence group, showing that the higher the whole body bioluminescence was 13 
days post inoculation, the lower the final ex vivo metastasis bioluminescence. However, 
since the majority of the bioluminescence signal emerges from the primary tumor 13 days 
post inoculation, whole body bioluminescence on day 13 is seemingly not predictive of 
metastatic progression in the VM-M3 model.  
 Since the proposed screen was not predictive of both ex vivo metastasis and 
primary tumor wet weight at the termination of the study, a new method of understanding 
the variation in VM-M3 tumor progression, invasion, and metastasis must be established. 
Understanding such variation in VM-M3 tumor progression is essential for determining if 
a particular treatment shows efficacy in the VM-M3 model or if some of the treated mice 
inherently have slower growing primary tumors and/or a slower metastatic progression. 
Other cancer models that have variable tumor growth attempt to classify treatment 
efficacy or slow tumor progression using mathematical modeling (64). However, such 
models have limitations.  
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 As a means of understanding both primary tumor growth and metastatic 
progression in each mouse in a study, each mouse may be used as their own control. 
Whole body bioluminescence can be compared before treatment and after treatment in 
each mouse individually. However, it may still be difficult to determine if the slow 
disease progression of a treated mouse is due to the treatment or due an inherent tendency 
of the mouse to progress more slowly in tumor growth and/or metastasis. Perhaps such an 
inherently slow progression needs to be analyzed on the molecular level.  
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Figure 24. Growth and metastasis of the VM-M3/Fluc tumor with bioluminescence 
imaging (A) and VM-M3 metastatic cancer model survival (B and C). A. 2 x 106 
VM-M3 cells were injected subcutaneously into the flank of the VM mouse. Dorsal 
images were taken on day 9, 18, and 29 post inoculation as described in Materials and 
Methods. The dorsal bioluminescence images of two representative mice (“Mouse 1” and 
“Mouse 2”) are pictured. B and C. 11 VM mice were inoculated subcutaneously into the 
flank with 2 x 106 VM-M3 cells. The survival of the 11 mice is displayed as a Kaplan-
Meir plot (B) and timeline (C).  
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Figure 25.  Luciferin kinetic curves. A. Two mice were administered 150mg/kg d-
luciferin in dPBS. The mice were anesthetized by isoflourane and imaged at the indicated 
times following luciferin administration. The photon flux from the whole body of the VM 
mouse was quantified using LivingImage software. The gold star indicates the time point 
at which a maximal photon flux was detected. The same two mice are pictured in A, B 
and C (labeled “Mouse 1” and “Mouse 2”). A. Time period when a maximal photon flux 
was detected. B. Time period before the maximal photon flux. C. Time period after the 
maximal photon flux. 
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Figure 26. Whole body bioluminescence day 5 post inoculation. 26 VM mice were 
inoculated with 2 x 106 VM-M3 cells and their whole body bioluminescence was 
analyzed 5, 8, and 13 days after inoculation. 16 mice were imaged using 150 mg/kg 
luciferin and 10 mice were imaged using 50 mg/kg luciferin. Each number represents a 
single mouse (e.g. 5.1). The photon flux for each mouse is presented as the summation of 
the total flux (photons/second) of the dorsal and lateral left side whole body images. Each 
tumor was implanted subcutaneously on the left flank of the mouse.  
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Figure 27. Whole body bioluminescence day 8 post inoculation. 26 VM mice were 
inoculated with 2 x 106 VM-M3 cells and their whole body bioluminescence was 
analyzed 5, 8, and 13 days after inoculation. 16 mice were imaged using 150 mg/kg 
luciferin and 10 mice were imaged using 50 mg/kg d-luciferin. Each number represents a 
single mouse (e.g. 5.1). The photon flux for each mouse is presented as the summation of 
the total flux (photons/second) of the dorsal and lateral left side whole body images. Each 
tumor was implanted subcutaneously on the left flank of the mouse.
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Figure 28. Whole body bioluminescence day 13 post inoculation. 26 VM mice were 
inoculated with 2 x 106 VM-M3 cells and their whole body bioluminescence was 
analyzed 5,8, and 13 days after inoculation. This figure displays the bioluminescence of 
all mice on day 13 post inoculation. The whole body bioluminescence of all 26 mice was 
analyzed using 150 mg/kg d-luciferin. Each number represents a single mouse (e.g. 5.1). 
The photon flux for each mouse is presented as the summation of the total flux 
(photons/second) of the dorsal (back) and lateral left side whole body images. Each tumor 
was implanted subcutaneously on the left flank of the mouse. A. The bioluminescence of 
each mouse is organized by mouse number. B. The bioluminescence of each mouse in A 
is organized from low to high photon flux. The cutoff for screening mice into a “low 
whole body luminescence” group and a “high whole body luminescence” group is 
indicated by a solid vertical line. 
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Figure 29. Screen whole body bioluminescence day 13 post inoculation. 3 VM-M3 
mice from the “low whole body bioluminescence” group and 6 VM-M3 mice from the 
“high whole body luminescence” group (Figure 29) were selected to continue in the 
screen. A. Day 13 whole body bioluminescence of the 9 mice chosen for the screen study 
from Figure 29. B. Lateral left whole body bioluminescence of the same 9 mice as A 
divided into “Primary Tumor Bioluminescence” (grey) and “Metastasis 
Bioluminescence” (red).   
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Figure 30. Screen primary tumor wet weight day 29 post inoculation. A. Primary 
tumor wet weight of each mouse in the screen study. B. Average primary tumor wet 
weight of 6 mice in the “high whole body bioluminescence” group and 3 mice in the “low 
whole body bioluminescence.” Data are represented as the mean primary tumor wet 
weight ± S.D. C. Percent of primary tumors above 0.3g. The red dashed line in A. 
indicates the 0.3g primary tumor wet weight cutoff. 
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Figure 31. Metastatic spread to the lung, liver, kidney, brain, and spleen. A. The 
bioluminescence of both sides of the lung, liver, kidney, brain, and spleen was added and 
presented as a single measure of metastasis for each mouse. B. Example of ex vivo 
metastasis bioluminescence. C. Average ex vivo metastasis bioluminescence for the 3 
mice in the “low whole body bioluminescence” and 6 mice in the “high whole body 
bioluminescence.” Data are presented as the mean photon flux ± S.D. D. Percent of ex 
vivo bioluminescence above 2 x 107 photons/ second. The red dashed line in A indicates 
the 2 x 107 photons/ second cutoff.  
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Figure 32. Correlation between primary tumor bioluminescence on day 13 and 
primary tumor wet weight at the termination (day 29) of the study. A linear 
correlation between day 13 primary tumor bioluminescence and day 29 primary tumor 
wet weight was determined for both the A. High whole body bioluminescence group and 
the B. Low whole body bioluminescence group. R2 values are shown. High whole body 
bioluminescence n = 6, low whole body bioluminescence n = 3.    
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Figure 33. Correlation between whole body bioluminescence on day 13 and 
metastasis at the termination (day 29) of the study. A linear correlation between the 
day 13 whole body bioluminescence and day 29 metastasis bioluminescence was 
determined for the A. High whole body bioluminescence group and B. Low whole body 
bioluminescence group. R2 values are shown. High whole body bioluminescence n = 5, 
low whole body bioluminescence n = 3.    
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Figure 34. Differentiating “primary tumor bioluminescence” from “metastasis 
bioluminescence.” Primary tumor bioluminescence was determined by defining a region 
of interest (ROI) surrounding the primary tumor bioluminescence. Metastasis 
bioluminescence was determined by defining a region of interest (ROI) surrounding the 
whole mouse body and subtracting the primary tumor bioluminescence from the whole 
body bioluminescence.  
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Appendix I 
 
 
 
 
A schematic representation of the major metabolic pathways in a representative 
eukaryotic cell. The metabolic pathways include glycolysis, the pentose phosphate 
pathway (PPP), the citric acid cycle, the electron transport chain (ETC), fatty acid 
synthesis (FAS), and fatty acid oxidation (FAO). The main energy substrates include 
fatty acids, glucose, and glutamine. Fatty acids from the cytosol are transported into the 
mitochondria through the activity of CPT-1. The fatty acids for fatty acid ß-oxidation can 
be derived either exogenously from the extracellular environment or endogenously 
through the metabolism of triglycerides stored in lipid droplets or through fatty acid 
synthesis catalyzed by the fatty acid synthase (FASN) enzyme. Glucose is imported from 
the extracellular space by the glucose transporters (GLUTs) and is then metabolized 
through glycolysis to produce pyruvate. Under aerobic conditions in normal cells, 
pyruvate is oxidized to acetyl-CoA and enters the TCA cycle in order to produce the 
reducing equivalents necessary for oxidative phosphorylation. When oxygen is low in 
normal cells, pyruvate is reduced to lactate and the oxidizing agent NAD+. The Pentose 
Phosphate Pathway (PPP) contributes to cell growth and proliferation through the 
generation of pentose sugars, for nucleic acid synthesis, and NADPH. The neutral amino 
acid glutamine is imported into the cell through uniport mechanisms. Glutamine provides 
ATP through substrate level phosphorylation in the TCA cycle when oxidative 
phosphorylation is deficient.  
 
 
Fa#y%Acids%%
Lactate%Lactate%
Cytoplasm%%
Extracellular%%
Fa#y%Acids%%
Acetyl7CoA%Malonyl%CoA%
FASN%
Oxaloacetate% Malate%
Mitochondria%%
FADH2% +% NADH%
Acetyl7CoA%FAO%
Outer%Mitochondrial%
Membrane%%
Inner%Mitochondrial%
Membrane%%
Fa#y%Acids%%CPT71%
H+% H+% H
+%
ETC% H+%+%ATP%%%
O2%!%2H2O%
Acetyl7CoA%
Pyruvate%
TCA%
Citrate%
Glucose%
Pyruvate%
Glucose767P%
Glycolysis%
Pentose%%
Phosphate%%
Pathway%
ATP%
Glutamine%
FADH2% +% NADH%
	  150	  
References 
 
1. Shrago, E., Woldegiorgis, G., Ruoho, A. E., and DiRusso, C. C.. 1995. Fatty acyl-CoA 
esters as regulators of cell metabolism. Prostaglandins Leukot. Essent. Fat. Acids. 
52: 163–166.  
2. Warburg, O.. 1956. Injuring of Respiration the Origin of Cancer Cells. Science (80-. ). 
123: 309–14. [online] http://www.ncbi.nlm.nih.gov/pubmed/13298683.  
3. Warburg, O., F. Wind, and E. Negelein. 1927. I . Killing-Off of Tumor Cells in Vitro . 
J. Gen. Physiol. 8: 519–530.  
4. Kiebish, M. a, X. Han, H. Cheng, J. H. Chuang, and T. N. Seyfried. 2008. Cardiolipin 
and electron transport chain abnormalities in mouse brain tumor mitochondria: 
lipidomic evidence supporting the Warburg theory of cancer. J. Lipid Res. 49: 
2545–56. [online] 
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=2582368&tool=pmcen
trez&rendertype=abstract (Accessed May 8, 2014).  
5. Pedersen - 1978 - Tumor Mitochondria and the Bioenergetics of Cancer Cells.pdf.  
6. Hanahan, D., and R. a. Weinberg. 2011. Hallmarks of cancer: The next generation. 
Cell. 144: 646–674. [online] http://dx.doi.org/10.1016/j.cell.2011.02.013.  
7. Crabtree, H. G.. 1929. Observations on the carbohydrate metabolism of tumours. 
Biochem. J. 23: 536–545.  
8. Ibsen, K. H.. 1961. The Crabtree effect: a review. Cancer Res. 21: 829–841.  
9. Sweet, I. R., M. Gilbert, E. Maloney, D. M. Hockenbery, M. W. Schwartz, and F. Kim. 
2009. Endothelial inflammation induced by excess glucose is associated with 
cytosolic glucose 6-phosphate but not increased mitochondrial respiration. 
Diabetologia. 52: 921–31. [online] 
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=2741088&tool=pmcen
trez&rendertype=abstract.  
10. Chance, B., and B. Hess. 1956. On the control of metabolism in ascites tumor cell 
suspensions. Ann. New York Acad. …. [online] 
http://onlinelibrary.wiley.com/doi/10.1111/j.1749-6632.1956.tb50908.x/abstract.  
11. Chance, B. H. and B.. 1961. VI. Chemical Events After Glucose Addition to Ascites 
Tumor Cells. J. Biol. Chem. 238: 239–246.  
12. Packer, L., and R. H. Golder. 1960. ARTICLE  : Correlation of Structural and 
Metabolic Changes Accompanying the Addition of Carbohydrates to Ehrlich 
Ascites Tumor Correlation of Structural and Metabolic Changes Accompanying 
the Addition of Carbohydrates to Ehrlich Ascites Tumor Cells *.  
13. Chance, B., and L. Packer. 1958. Light-scattering and absorption effects caused by 
addition of adenosine diphosphate to rat-heart-muscle sarcosomes. Biochem. J. 68: 
295–297.  
14. Rossignol, R., R. Gilkerson, R. Aggeler, K. Yamagata, S. J. Remington, and R. A. 
Capaldi. 2004. Energy Substrate Modulates Mitochondrial Structure and Oxidative 
Capacity in Cancer Cells. 985–993.  
15. Raschke, W. C., S. Baird, P. Ralph, and I. Nakoinz. 1978. Functional macrophage cell 
lines transformed by Abelson leukemia virus. Cell. 15: 261–267.  
16. Diaz-Ruiz, R., M. Rigoulet, and A. Devin. 2011. The Warburg and Crabtree effects: 
On the origin of cancer cell energy metabolism and of yeast glucose repression. 
	  151	  
Biochim. Biophys. Acta - Bioenerg. 1807: 568–576. [online] 
http://dx.doi.org/10.1016/j.bbabio.2010.08.010.  
17. Guppy, M., E. Greiner, and K. Brand. 1993. The role of the Crabtree effect and an 
endogenous fuel in the energy metabolism of resting and proliferating thymocytes. 
Eur. J. Biochem. 212: 95–99.  
18. Rodríguez-Enríquez, S., O. Juárez, J. S. Rodríguez-Zavala, and R. Moreno-Sánchez. 
2001. Multisite control of the Crabtree effect in ascites hepatoma cells. Eur. J. 
Biochem. 268: 2512–2519.  
19. Henn, A., S. Lund, M. Hedtjärn, A. Schrattenholz, P. Pörzgen, and M. Leist. 2009. 
The suitability of BV2 cells as alternative model system for primary microglia 
cultures or for animal experiments examining brain inflammation. ALTEX  Altern. 
zu Tierexperimenten. 26: 83–94.  
20. Elkalaf, M., M. Anděl, and J. Trnka. 2013. Low Glucose but Not Galactose Enhances 
Oxidative Mitochondrial Metabolism in C2C12 Myoblasts and Myotubes. PLoS 
One. 8: e70772. [online] http://dx.plos.org/10.1371/journal.pone.0070772.  
21. Marroquin, L. D., J. Hynes, J. a. Dykens, J. D. Jamieson, and Y. Will. 2007. 
Circumventing the crabtree effect: Replacing media glucose with galactose 
increases susceptibility of hepG2 cells to mitochondrial toxicants. Toxicol. Sci. 97: 
539–547.  
22. Fry, M., and D. E. Green. 1981. Cardiolipin requirement for electron transfer in 
complex I and III of the mitochondrial respiratory chain. J. Biol. Chem. 256: 
1874–1880.  
23. Mileykovskaya, Eugenia Dowhan, W.. 2012. Cardiolipin-Dependent Formation of 
Mitochondrial Respiratory Supercomplexes. Chem Phys Lipids. 29: 997–1003.  
24. Haines, T. H., and N. a Dencher. 2002. Cardiolipin: a proton trap for oxidative 
phosphorylation. FEBS Lett. 528: 35–39. [online] 
http://linkinghub.elsevier.com/retrieve/pii/S0014579302032921.  
25. Chicco, A. J., and G. C. Sparagna. 2007. Role of cardiolipin alterations in 
mitochondrial dysfunction and disease. Am. J. Physiol. Cell Physiol. 292: C33–
C44.  
26. Zhang, M., E. Mileykovskaya, and W. Dowhan. 2002. Gluing the Respiratory Chain 
Together. CARDIOLIPIN IS REQUIRED FOR SUPERCOMPLEX 
FORMATION IN THE INNER MITOCHONDRIAL MEMBRANE. J. Biol. 
Chem. 277: 43553–43556. [online] 
http://www.jbc.org/cgi/doi/10.1074/jbc.C200551200.  
27. Pfeiffer, K., V. Gohil, R. a. Stuart, C. Hunte, U. Brandt, M. L. Greenberg, and H. 
Schagger. 2003. Cardiolipin Stabilizes Respiratory Chain Supercomplexes. J. Biol. 
Chem. 278: 52873–52880. [online] 
http://www.jbc.org/cgi/doi/10.1074/jbc.M308366200.  
28. Ames, B. N., M. K. Shigenaga, and T. M. Hagen. 1995. Mitochondrial decay in aging. 
Biochim Biophys Acta. 1271: 165–170.  
29. Paradies, G., G. Petrosillo, V. Paradies, and F. M. Ruggiero. 2010. Oxidative stress, 
mitochondrial bioenergetics, and cardiolipin in aging. Free Radic. Biol. Med. 48: 
1286–95. [online] http://www.ncbi.nlm.nih.gov/pubmed/20176101 (Accessed 
December 3, 2014).  
	  152	  
30. Xu, Y., R. I. Kelley, T. J. J. Blanck, and M. Schlame. 2003. Remodeling of 
cardiolipin by phospholipid transacylation. J. Biol. Chem. 278: 51380–5. [online] 
http://www.ncbi.nlm.nih.gov/pubmed/14551214.  
31. Schlame, M., and M. Ren. 2006. Barth syndrome, a human disorder of cardiolipin 
metabolism. FEBS Lett. 580: 5450–5455. [online] 
http://linkinghub.elsevier.com/retrieve/pii/S001457930600857X.  
32. Barth, P. G., H. R. Scholte, J. a Berden, J. M. Van der Klei-Van Moorsel, I. E. Luyt-
Houwen, E. T. Van ’t Veer-Korthof, J. J. Van der Harten, and M. a Sobotka-
Plojhar. 1983. An X-linked mitochondrial disease affecting cardiac muscle, 
skeletal muscle and neutrophil leucocytes. J. Neurol. Sci. 62: 327–355.  
33. Huysentruyt, L. C., P. Mukherjee, D. Banerjee, L. M. Shelton, and T. N. Seyfried. 
2008. Metastatic cancer cells with macrophage properties: evidence from a new 
murine tumor model. Int. J. Cancer. 123: 73–84. [online] 
http://www.ncbi.nlm.nih.gov/pubmed/18398829 (Accessed April 26, 2014).  
34. Di Biase, a, S. Salvati, and G. S. Crescenzi. 1989. Analysis of brain and myelin lipids 
by high-performance thin layer chromatography and densitometry. Neurochem. 
Res. 14: 153–6. [online] http://www.ncbi.nlm.nih.gov/pubmed/2471093.  
35. Folch, J., M. Lees, and G. H. S. Stanley. 1957. ARTICLE  : A SIMPLE METHOD 
FOR THE ISOLATION AND PURIFICATION OF TOTAL LIPIDES FROM 
ANIMAL TISSUES.  
36. Kasperzyk, J. L., a d’Azzo, F. M. Platt, J. Alroy, and T. N. Seyfried. 2005. Substrate 
reduction reduces gangliosides in postnatal cerebrum-brainstem and cerebellum in 
GM1 gangliosidosis mice. J. Lipid Res. 46: 744–51. [online] 
http://www.ncbi.nlm.nih.gov/pubmed/15687347 (Accessed April 8, 2014).  
37. Bligh, E. G., and W. G. Dyer. 1959. A Rapid Method of Total Lipid Extraction and 
Purification. Can. J. Biochem. Physiol. 37: 911–917.  
38. Kiebish, M. a, X. Han, H. Cheng, J. H. Chuang, and T. N. Seyfried. 2008. Cardiolipin 
and electron transport chain abnormalities in mouse brain tumor mitochondria: 
lipidomic evidence supporting the Warburg theory of cancer. J. Lipid Res. 49: 
2545–56. [online] 
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=2582368&tool=pmcen
trez&rendertype=abstract (Accessed November 13, 2014).  
39. Kiebish, M. a, X. Han, H. Cheng, and T. N. Seyfried. 2009. In vitro growth 
environment produces lipidomic and electron transport chain abnormalities in 
mitochondria from non-tumorigenic astrocytes and brain tumours. ASN Neuro. 1: 
125–138.  
40. Houtkooper, R. H., and F. M. Vaz. 2008. Cardiolipin, the heart of mitochondrial 
metabolism. Cell. Mol. Life Sci. 65: 2493–506. [online] 
http://www.ncbi.nlm.nih.gov/pubmed/18425414 (Accessed December 3, 2014).  
41. Hard, G. C.. 1970. Some biochemical aspects of the immune macrophage. Br. J. Exp. 
Pathol. 51: 97–105. [online] 
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=2072214&tool=pmcen
trez&rendertype=abstract.  
42. Rodriguez-Prados, J.-C., P. G. Traves, J. Cuenca, D. Rico, J. Aragones, P. Martin-
Sanz, M. Cascante, and L. Bosca. 2010. Substrate Fate in Activated Macrophages: 
A Comparison between Innate, Classic, and Alternative Activation. J. Immunol. 
	  153	  
185: 605–614. [online] 
http://www.jimmunol.org/cgi/doi/10.4049/jimmunol.0901698.  
43. Tannahill, G. M., a M. Curtis, J. Adamik, E. M. Palsson-McDermott, a F. McGettrick, 
G. Goel, C. Frezza, N. J. Bernard, B. Kelly, N. H. Foley, L. Zheng, a Gardet, Z. 
Tong, S. S. Jany, S. C. Corr, M. Haneklaus, B. E. Caffrey, K. Pierce, S. Walmsley, 
F. C. Beasley, E. Cummins, V. Nizet, M. Whyte, C. T. Taylor, H. Lin, S. L. 
Masters, E. Gottlieb, V. P. Kelly, C. Clish, P. E. Auron, R. J. Xavier, and L. a J. 
O’Neill. 2013. Succinate is an inflammatory signal that induces IL-1β through 
HIF-1α. Nature. 496: 238–42. [online] 
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=4031686&tool=pmcen
trez&rendertype=abstract.  
44. Liu, T. F., C. M. Brown, M. El Gazzar, L. McPhail, P. Millet, a. Rao, V. T. 
Vachharajani, B. K. Yoza, and C. E. McCall. 2012. Fueling the flame: bioenergy 
couples metabolism and inflammation. J. Leukoc. Biol. 92: 499–507. [online] 
http://www.jleukbio.org/cgi/doi/10.1189/jlb.0212078.  
45. Brown, G. C., N. Foxwell, and S. Moncada. 1998. Transcellular regulation of cell 
respiration by nitric oxide generated by activated macrophages. FEBS Lett. 439: 
321–324. [online] 
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt
=Citation&list_uids=9845346. 
46. Brown, G. C.. 1994. Nanomolar concentrations of nitric oxide reversibly inhibit 
synaptosomal respiration by competing with oxygen at cytochrome oxidase. FEBS 
Lett. 356: 295–298.  
47. Petrosillo, G., N. Di Venosa, F. M. Ruggiero, M. Pistolese, D. D’Agostino, E. 
Tiravanti, T. Fiore, and G. Paradies. 2005. Mitochondrial dysfunction associated 
with cardiac ischemia/reperfusion can be attenuated by oxygen tension control. 
Role of oxygen-free radicals and cardiolipin. Biochim. Biophys. Acta. 1710: 78–86. 
[online] http://www.sciencedirect.com/science/article/pii/S0005272805002343.  
48. Julienne, C. M., M. Tardieu, S. Chevalier, M. Pinault, P. Bougnoux, F. Labarthe, C. 
Couet, S. Servais, and J.-F. Dumas. 2014. Cardiolipin content is involved in liver 
mitochondrial energy wasting associated with cancer-induced cachexia without the 
involvement of adenine nucleotide translocase. Biochim. Biophys. Acta - Mol. 
Basis Dis. 1842: 726–733. [online] 
http://www.sciencedirect.com/science/article/pii/S0925443914000428.  
49. Aguer, C., D. Gambarotta, R. J. Mailloux, C. Moffat, R. Dent, R. McPherson, and 
M.-E. Harper. 2011. Galactose Enhances Oxidative Metabolism and Reveals 
Mitochondrial Dysfunction in Human Primary Muscle Cells. PLoS One. 6: e28536. 
[online] http://dx.plos.org/10.1371/journal.pone.0028536.  
50. Domenis, R., E. Bisetto, D. Rossi, M. Comelli, and I. Mavelli. 2012. Glucose-
Modulated Mitochondria Adaptation in Tumor Cells: A Focus on ATP Synthase 
and Inhibitor Factor 1. Int. J. Mol. Sci. 13: 1933–1950. [online] 
http://www.mdpi.com/1422-0067/13/2/1933/. 
51. Leventis, P. a., and S. Grinstein. 2010. The Distribution and Function of 
Phosphatidylserine in Cellular Membranes. Annu. Rev. Biophys. 39: 407–427. 
[online] 
http://www.annualreviews.org/doi/abs/10.1146/annurev.biophys.093008.131234.  
	  154	  
52. Roberts, G. G., and A. P. Hudson. 2006. Transcriptome profiling of Saccharomyces 
cerevisiae during a transition from fermentative to glycerol-based respiratory 
growth reveals extensive metabolic and structural remodeling. Mol. Genet. 
Genomics. 276: 170–86. [online] http://www.ncbi.nlm.nih.gov/pubmed/16741729.  
53. Lai, L.-C., a. L. Kosorukoff, P. V. Burke, and K. E. Kwast. 2006. Metabolic-State-
Dependent Remodeling of the Transcriptome in Response to Anoxia and 
Subsequent Reoxygenation in Saccharomyces cerevisiae. Eukaryot. Cell. 5: 1468–
1489. [online] http://ec.asm.org/cgi/doi/10.1128/EC.00107-06.  
54. Vance, J. E., and G. Tasseva. 2013. Formation and function of phosphatidylserine and 
phosphatidylethanolamine in mammalian cells. Biochim. Biophys. Acta - Mol. Cell 
Biol. Lipids. 1831: 543–554. [online] 
http://linkinghub.elsevier.com/retrieve/pii/S1388198112001874.  
55. Böttinger, L., S. E. Horvath, T. Kleinschroth, C. Hunte, G. Daum, N. Pfanner, and T. 
Becker. 2012. Phosphatidylethanolamine and cardiolipin differentially affect the 
stability of mitochondrial respiratory chain supercomplexes. J. Mol. Biol. 423: 
677–86. [online] 
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3480645&tool=pmcen
trez&rendertype=abstract.  
56. Schenkel, L. C., and M. Bakovic. 2014. Formation and Regulation of Mitochondrial 
Membranes. 2014.  
57. Francia, G., W. Cruz-Munoz, S. Man, and R. S. Kerbel. 2011. Mouse models of 
advanced spontaneous metastasis for experimental therapeutics. Nat Rev Cancer. 
11: 135–141.  
58. Flatmark, K., G. M. Mælandsmo, M. Martinsen, H. Rasmussen, and Ø. Fodstad. 2004. 
Twelve colorectal cancer cell lines exhibit highly variable growth and metastatic 
capacities in an orthotopic model in nude mice. Eur. J. Cancer. 40: 1593–1598. 
[online] http://linkinghub.elsevier.com/retrieve/pii/S0959804904002382.  
59. Kellar, A., C. Egan, and D. Morris. 2015. Preclinical Murine Models for Lung 
Cancer: Clinical Trial Applications. Biomed Res. Int. 2015: 1–17. [online] 
http://www.hindawi.com/journals/bmri/2015/621324/.  
60. Hallden, G., R. Hill, A. Anand, T.-C. Liu, Y. Wang, N. R. Lemoine, J. Francis, L. 
Hawkins, and D. Kirn. 2003. Novel Immunocompetent Murine Tumor Models for 
the Assessment of Replication-Competent Oncolytic Adenovirus Ef cacy. Gene 
Ther. 8: 412–424.  
61. Aswendt, M., J. Adamczak, S. Couillard-Despres, and M. Hoehn. 2013. Boosting 
Bioluminescence Neuroimaging: An Optimized Protocol for Brain Studies. PLoS 
One. 8: 1–9.  
62. Berger, F., R. Paulmurugan, S. Bhaumik, and S. S. Gambhir. 2008. Uptake kinetics 
and biodistribution of 14C-d-luciferin-a radiolabeled substrate for the firefly 
luciferase catalyzed bioluminescence reaction: Impact on bioluminescence based 
reporter gene imaging. Eur. J. Nucl. Med. Mol. Imaging. 35: 2275–2285.  
63. Xenogen. 2005. Luciferin and In Vivo Imaging. 1–2.  
64. Laajala, T. D., J. Corander, N. M. Saarinen, K. Mäkelä, S. Savolainen, M. I. 
Suominen, E. Alhoniemi, S. Mäkelä, M. Poutanen, and T. Aittokallio. 2012. 
Improved statistical modeling of tumor growth and treatment effect in preclinical 
	  155	  
animal studies with highly heterogeneous responses in vivo. Clin. Cancer Res. 18: 
4385–4396.   
 
